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ABSTRACT
The 52 kDa FK506 binding protein (h52) is a key positive regulator of Androgen
Receptor (AR) in cellular and animal models and is an attractive target for the treatment
of prostate cancer. Human FKBP52 is a known regulatory protein and co-chaperone
that has been shown to play an important role in the regulation of the AR signaling
pathway, and in the development of the male sexual phenotype. Cellular studies in
mammalian and yeast cells reveal that FKBP52 is a positive regulator of AR,
glucocorticoid receptor (GR), and progesterone receptor (PR), potentiating receptormediated gene expression up to 60-fold in some systems.
In targeting FKBP52, a thorough investigation and understanding of the structural
elements that underlay its function is necessary. This permits a logical approach in
targeting specific interaction motifs, such as those that exist between the AR and
FKBP52. Here we use a cross-species comparative approach to analyze the
mechanisms of potentiation and the functional difference between FKBP52 and Danio
rerio (Zebra fish) FKBP52 (DrFKBP52). In this study we have taken advantage of this by
comparing their differences to identify additional important domains and residues.
Through this study we have identified the FK2 domain, a previously uncharacterized,
non-functional domain, as playing a role FKBP52 activity. This observation dispels the
notion that the FK1 domain is the sole regulatory domain, specifically the proline-rich
loop. Though both have the proline-rich loop, its presence is not indicative of
potentiation activity. A genetic selection screen generated in Saccharomyces cerevisiae
for gain of potentiation activity, in a library of randomly mutated DrFKBP52 genes,
identified two residues: position 111 in the FK1 domain and 157 in the FK2 domain as
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being the critical residues for activation of receptor potentiation by DrFKBP52. In both
the yeast model and mammalian cells, the DrFKBP52 mutation A111V, which is an
adjacent residues downstream of the proline-rich loop, confer significant potentiation
activity, whereas the same mutation introduced to FKBP52 only slightly elevates
activity. Three dimensional crystal structure homology modeling by I-TASSER indicate
that when alanine is replaced by valine at position 111 this change affect both the
surface charge (to more neutral) and the hydrophobicity (to more hydrophobic) in
vicinity. We believe this change induces an open conformation of the proline rich loop
notch, allowing for sufficient surface area for AR interaction. A second residue in the
FK2 region, T157R, also greatly influences potentiation. Moreover, the DFKBPr52:
A111V _T157R double mutant potentiated hormone signaling as well as wild-type
hFKBP52. Collectively these results suggest that specific residues in both FK1 and FK2
domain are critical for full activity and are involved in receptor interactions, which
potentiates steroid hormone receptor activity. These newly identified domains and
residues could possibly become targets for inhibitors as they could be key residues to
specifically disrupt AR-FKBP52 association.
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CHAPTER 1: INTRODUCTION
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1.1 ANDROGEN RECEPTOR IN DISEASE
The Androgen receptor (AR) and androgens play a critical role in the regulation of
male sexual development and physiological processes, specifically the development
and maintenance of the male reproductive system. Given its crucial role in normal male
physiology, deregulation of AR and androgen signaling pathways has been
implemented in a variety of disorders and diseases such as: Androgen Insensitivity
Syndrome (AIS), Spinal bulbar muscular atrophy (SBMA), and Prostate cancer (PCa).
(38)
1.1.2 Androgen Insensitivity Syndrome (AIS)
The essential role of AR and androgens in male sexual physiology has been
established through androgen insensitivity syndrome (AIS). This genetic disorder is a
condition that results in the partial or complete inability of the target cells to respond to
androgens. It is primarily caused by missense and nonsense AR mutations, resulting in
amino acid substitution in the ligand binding domain (LBD) and DNA binding domain
(DBD). Defective AR proteins are unable to bind androgens or androgen response
elements (AREs). AR’s inability to bind AREs inhibits the expression of androgen target
genes in the body, dramatically affecting male sexual phenotype. Depending on the
severity of receptor mutations, individuals with AIS can fall into two categories, complete
AIS (CAIS) or partial AIS. Affected individuals have a Y chromosome, but still have mild
to severe defects in external virilization. Mutation of part, or deletion of the entire AR
gene leads to CAIS, resulting in a dysfunctional receptor protein that cannot respond to
circulating androgens. CAIS can also be caused by an absence of androgens in the
blood. Patients with CAIS display feminized external genitalia, intra-abdominal testes
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and fail to develop secondary sex characteristics at puberty. Except for the absence of a
uterus most CAIS individuals maintain all other female phenotype (44). The clinically
relevant AR mutant, P723S, was identified in genital skin fibroblasts from a patient with
complete androgen-insensitivity syndrome. This mutant was observed to have normal
maximum androgen binding, but elevated equilibrium dissociation constants (45). Its
activity was assessed in yeast and mammalian cells, and, as expected, the P723S
mutant had minimal responsiveness to high amounts of dihydrotestosterone (DHT).
Interestingly, in the presence of FKBP52, an Hsp90-associated co-chaperone, AR
P723S matched the activity of wt-AR. Thus, the AR P723S mutant displays increased
dependence on FKBP52 for function.
Partial AIS is also caused by AR mutations, which alter the structural
conformation of AR and diminish AR responsiveness to androgens. The structural
modification of the androgen receptor decreases the receptor’s ability to bind hormones
with high affinity, leading to reduced AR-mediated gene expression in target tissues. As
a result, patients present with a number of physiological defects in male reproductive
development (16). Interestingly, many of the defects seen in PAIS individuals correlate
with those seen in fkbp52-deficient mice (6).
1.1.3 Spinal Bulbar Muscular Atrophy (SBMA)
Spinal bulbar muscular atrophy (SBMA), or Kennedy’s disease, is an X-linked
hereditary neurodegerative disease caused by expansion of CAG codon repeats. These
repeats code for a polyglutamine (polyQ) tract at the amino terminus of the androgen
receptor. Polymorphic repeat ranges from 11-35 CAGs in normal males and 37-65
CAGs in the SBMS, causing a dramatic impact on AR transactivation. Like native AR,
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this ligand-dependent neurotoxic AR elicits effects through the normal steroid hormone
receptor maturation cycle. Heat shock protein 90 (Hsp90) plays a critical role in AR
maturation, contributing to receptor stability and the high affinity hormone binding
conformation of the receptor. Once hormone is bound, the polyQ tract of AR is exposed,
allowing either the association with other AR polyQ regions or abnormal conformational
changes in AR. This leads to aggregates that are resistant to proteosomal degradation
(46). Although transactivation is compromised, this doesn’t result in a loss of
transcriptional activity. Therefore, gain-of-neurotoxic effects caused by aggregates form
intranuclear inclusion in motor neurons of the brain stem and spinal cord result in
transcriptional deregulation. However, the exact molecular mechanism is still unclear.
The physiological manifestations are muscle cramps, arm and leg weakness, difficulty
speaking and swallowing and increased incidence of AIS. Treatment using antiandrogen such as Leuprorelin, Flutamide (reduce testosterone levels) and Dutasteride
(5-α-reductase inhibitor) showed little to no improvement in SBMA clinical trails.
Interestingly, the dutasteride study showed that higher levels of testosterone are
associated with increased muscle strength and function (51). Hsp90 inhibitors (17-AAG
and 17-DMAG) developed for the treatment of cancer have been studied for treatment
in an SBMA mouse model. Both Hsp90 inhibitors were shown to decrease intranuclear
aggregate formation, leading to an improvement in motor performance. Unfortunately,
clinical trials for these inhibitors have not lasted more than 6 months due to toxicity
including temporary blindness and liver toxicity (51).

The lack of efficacy in anti-

androgens and toxic Hsp90 inhibitors demonstrates the need to develop other
therapeutic targets for this disease.
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1.1.4 Prostate Cancer
Prostate cancer is a widely recognized disease that has become increasingly
prevalent in American men. Except for non-melanoma skin cancer, prostate cancer is
the most common diagnosed malignancy among men in the United States. It is the most
common in males between the ages of 50-80 and is the second leading cause of cancer
death among men of all races, killing approximately 1 out of 36 males a year (1, 2, 52,
53). Though PC affects all races it is most prevalent in the African American community,
yet it has become more pervasive among Hispanics and Caucasians. The cause of PC
is still unclear, however, scientists have found several causal links. Several rick factors
include race, environment, age, obesity and heredity (49, 44).
Prostate cancer can be categorized into two groups, early stage and late stage.
Early stage PC is usually characterized by the presence of abnormal cells and slow
tumor growth that has not spread to surrounding tissues. At this stage treatment
methods are more simplistic ranging from watchful waiting, surgery, radiation therapy,
and androgen ablation therapy. In this case hormone therapy is the most commonly
used since androgens induce AR gene activation and play a necessary role in
maintaining the integrity of the prostate gland (2, 44, 50). Invariably, because of the
evolutionary nature of cancer, the disease recurs with a phenotype resistant to further
hormonal manipulations, thus beginning the catastrophic progression to late stage PC;
also known as castration-resistant prostate cancer (CRPC). Late stage PC is a much
more aggressive and complex cancer that is characterized as such because of the
multifaceted avenues that PC utilizes for proliferation and survival. Nevertheless,
researchers have slowly begun uncovering avenues by which CRPC mediates aberrant
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AR activation in the presence of minimal to no androgens. It is important to note that in
cell culture abnormal AR activation, in the absence of androgens, can be induced by
one or more of the following pathways: mutations in the AR gene, permitting
promiscuous ligand binding behavior, AR overexpression, hyperactive splice variants,
and activation of the AR by growth factors and cytokines (54). In addition, stimulation of
the cAMP-dependent protein kinase (PKA) pathway, interleukin-6 (IL-6), growth factors
(55, 56, 57) expression of co-regulatory molecules, crosstalk with other intracellular
signaling pathways (Wnt, NF-kB, bcl2/bcl-xL, PI3K/Akt) (58, 59, 60, 61) and bonederived factors (64), also have roles in aberrant AR transactivation.
Although prostate tumor growth is independent of androgens, it still remains
dependent on a functional AR for cancer cell growth and survival (65, 66).

It is

becoming increasingly evident that late stage PC tumors consist of multiple cells
containing different AR mutations, which can be activated by one or more signaling
pathways. Interestingly, spontaneously occurring AR mutations are observed after
androgen ablation therapy. The mutations that seem to cause the most detrimental
effects are near or in the ligand-binding domain (LBD) and N-terminal domain (NTD)
and these include Q668P, I671F, M523V, and G524D (65, 62). In vitro studies
determined that all mutants displayed a 2- to 4-fold increase in AR activity in response
to dihydrotestosterone (DHT), estradiol, progesterone, adrenal androgens and AR
antagonist (hydroflutamide). Structural studies showed a decrease in the hydrophobic
surface of the LBD, suggesting an altered intra-domain communication between the
NTD and LBD possibly mediating the activity of AR variants. Additionally, some mutants
have the capacity to form intra-molecular non-covalent bonds, making it more probable
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that conformational changes induce their transactivation properties (63, 65).
Researchers also implicated overexpression of AR at the mRNA and protein
level in CRPC, suggesting that a role for transcriptional regulation of the AR gene could
be one of the major causes of AR dysregulation. In most cases increased AR
expression occurs without gene amplification and may be due to altered transcriptional
regulation. Transcriptional co-activators play a key role in the expression of a wide
variety of genes, including AR. These co-activators bind to DNA in a specific sequential
manner and positively or negatively affect gene expression. The human AR is encoded
by one gene located on the X-chromosome. Characterization of the human AR
promoter region determined that it lacks a TATA-box and a CCAAT-box. Several
transcription factors have been reported to be responsible for controlling AR
transcription and promoting PC. Notable transcription factors (TF) that augment AR
gene expression in PC are Sp1, Foxo3a, mutated p53, LEF1, NFkB, FEN1, Betacatenin and cAMP (66, 67, 78). These nuclear proteins positively regulate AR
transcription and promote growth of PC cells. Each uses a diverse pathway to exert
effect. For example the Wnt-1/β-catenin pathway leads to activation of the LEF1
complex and increases AR transcription. Several studies have indicated that
progression to CRPC is associated with AR overexpression, and that AR inhibition
represses tumor growth in PC, even in CRPC (69, 70, 71, 72).
As researchers uncover the many facets of PC progression, the treatment
paradigm continues to shift to more difficult and complex strategies in the recent years.
Few effective therapies exist for the treatment of castration-resistant prostate cancer.
Castration-resistant tumor growth is lethal and accounts for more 30,000 deaths in the
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United States yearly. Median survival from the time of diagnosis for CRPC is between 23 years (75). Most therapies and treatments are directed towards androgens and the
androgen receptor. The AR signaling pathway in CRPC can activate gene expression
despite very low circulating levels of androgens. As aforementioned, AR signaling is
critical for growth and survival of CRPC and a majority of castration resistant tumors still
rely on AR activity for proliferation, making AR a rational target for CRCP. This fact is
further corroborated by clinical efficacy of androgen synthesis inhibitors (CYP17) and
the second-generation AR antagonist MDV3100. Second line hormonal therapy, CYP17
and MDV3100, were recently approved by the US FDA for treatment of CRPC for its
cumulative improvement in patient population survival (74).
1.2 TREATMENTS
1.2.1 CYP17 Inhibitors: Abiraterone (Zytiga)
Cytochrome P450 17A1 is an enzyme found in the adrenal cortex that is encoded
by the CYP17A1 gene. This monooxygenase is localized in the Endoplasmic reticulum,
and catalyzes the synthesis of cholesterol, steroids, and other lipids. It is comprised of
17α-hydroxyase and 17,20-lyase activity and is a critical enzyme in the steroidgenic
pathways that produce progestins, mineralocorticoids, glucocorticoids, androgens and
estrogens. CYP17 inhibitors, abiraterone acetate, orteronel, and galeterone block the
biosynthesis of androgens by inhibiting the CYP17A1 enzyme. However, only
abiraterone (Zytige) received FDA approval in 2011 for the treatment of metastatic
CRPC. Androgens are made from dehydroepiandrosterone (DHEA), which is derived
from cholesterol. This four-step process begins when cholesterol is shuttled into the
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mitochondria by steroidogenic acute regulatory protein (StAR). Cholesterol is converted
to pregnenolone by the cholesterol side chain cleavage enzyme, Cytochrome P450.
Pregnenolone then undergoes 17α-hydroxylation by microsomal Cytochrome P450c17.
Finally, 17-OH pregnenolone is converted to DHEA by the 17,20 lyase activity of
Cytochrome P450c17, which is where abiraterone acts to inhibit (75, 76).
Cytochrome P45017A1 is a key enzyme in cortisol synthesis via its 17αhydroxylase activity and plays a central role in androgen biosynthesis with its 17,20lyase activity catalyzing the conversion of 17-hydroxypregnenolone to the main
androgen precursor DHEA (77). These therapeutic agents have the capacity to bind the
enzyme’s active site and mimic the substrate, thereby inhibiting enzyme activation.
CYP17 inhibitors target steroidogenic pathways in testicular, adrenal/normal prostatic
tissues and PC cells (78). However, side effects such as hypertension, edema, and
hypokalemia were observed due to mineralocorticoid build up. This was counteracted
through the combined administration with prednisone. It is believed that prednisone
decreases the adverse effect of excess mineralocorticoid by suppressing ACTH release
from the pituitary gland, thus disrupting its pathway (78). A 50% reduction in prostate
specific antigen (PSA) levels is seen in approximately 60% of patients when abiraterone
and prednisone are administered together. Clinical trials have determined that this drug
is successful in eradicating the minimal amounts of androgens produced in the adrenal
and intratumoral production of androgens (79).
1.2.2 MDV3100: Enzalutamide (Xtandi)
MDV3100 is a non-steroidal antagonist of AR that binds directly to the LBD of
AR, inhibiting subsequent events that lead to gene expression and CRPC progression.
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Castration-resistant prostate cancer is commonly associated with increased levels of
AR gene expression, which can occur through AR gene amplification and AR slice
variants (80) concluded that high AR levels alone were sufficient to cause the transition
from hormone sensitive to hormone-resistant PC in mouse xenograft models, which
were derived from men with hormone-refractory PC. The mechanisms of this transition
are still unclear. However, this same study demonstrated that overexpression of AR
propagated an imbalance in nuclear receptor NCoR, a co-repressor, recruitment to the
PSA promoters (KLK3 and KLK2). This observation suggests that a modest change in
the levels of AR protein can augment co-activator and/or co-repressor assembled to the
promoter, thus affecting AR transactivation (81). With this said AR is the key functional
component in the progression of CRCP. MDV3100 unlike its predecessor, bicalutamide,
does not promote translocation of AR to the nucleus. Alternatively, MDV3100 prevents
binding of AR to DNA, and co-activators, it binds the AR with higher affinity, down
regulate PSA and TMPRSS2 and induces apoptosis in VCaP cells (71, 80). Since
MDV3100 binds to the androgen receptor and blocks all subsequent actions, it can inhibit the
growth of prostate cancer cells, which have failed standard hormonal therapies and even
chemotherapies. The dramatic improvement in patient survival has made MDV3100 (Xtandi)

the treatment of choice for CRPC.
As with most PC therapies, not all patients respond to drug treatment and most
patients who initially respond to treatment will develop resistance. Although both of
these drugs seem to be an answer to the CRPC dilemma, another paradigm shift
occurs making novel therapies essential for the further management of PC and CRPC.
Most cancers seem to have an evolutionary survival advantage, which allows tumors to
thrive in the most obscure circumstances. This phenomenon is seen with the
10

development of abiraterone resistance in a castration-resistant VCaP xerograph mouse
model. Relapse is caused by up-regulated CYP17 expression, suggesting that
abiraterone exerts selection pressure on cell survival and up-regulates intratumoral
CYP17 expression (83) and/or induces AR and AR splice variants that confer ligandindependent AR transactivation. MDV3100 also succumbs to the same fate, MDV3100
resistance. Mechanisms of resistance are still unclear, but may be due to AR mutations
that confer drug resistance (84), splice variants that lead to constitutive ligandindependent AR activation, or alternative signaling pathways. Activation of the PI3K
signaling pathway by the loss of PTEN has been shown to impair AR gene expression
leading to decreased dependence on AR signaling. PTEN-null mouse models treated
with MDV3100 demonstrated 25- to 50-fold decreases in cytoplasmic mRNA levels of
AR dependent genes with increased phosphorylation of PI3K pathways such as AKT.
This was suppressed by concurrent treatment with a PI3K inhibitor. Transcriptome
analyses reveled that activation of the PI3K pathway is associated with repressed
androgen signaling in vivo and in vitro, and may be responsible for the castrationresistant phenotype observed in MDV3100 resistance (85). Cumulatively, the data
indicate that AR and PI3K are cross-regulated by reciprocal feedback, thus, inhibition of
one activates the other, maintaining tumor cell survival. Therapeutic drugs, although
successful, eventually fail due to drug resistance, which necessitates the continued
development of novel therapies that can regulate prostate cancer signaling pathways.
1.2.3 Hsp90 Inhibitors:17-AAG (Tanespimycin) and 17-DMAG (Alvespimycin)
A large number of oncogenic proteins are overexpressed in cancer cells and
inhibiting the function of these proteins is also essential in controlling the progression of
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cancer. Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that
regulates the folding of over 300 nascent client proteins (86). This evolutionary
conserved chaperone maintains cell homeostasis in proteotoxic stress conditions by
binding unstable proteins and prevents protein degradation and aggregation. While
overexpression occurs for many oncoproteins, mutations accumulate facilitating cancer
cell survival through Hsp90 stabilizing events.
Hsp90 also plays a pivotal role in the integrity of the steroid hormone receptors,
and its association is necessary for hormone receptors to achieve the high affinity
hormone binding conformation. Because Hsp90 is vital for AR structural integrity, it too
has been identified as a possible therapeutic target in CRPC. Hsp90 dynamic
chaperoning occurs when ATP binds to the N-terminal domain, and ATP hydrolysis by
Hsp90 facilitates a conformational cycle that is essential for its chaperone activity. The
Hsp90 inhibitor, geldanamycin, binds directly to the N-terminal ATP-binding pocket,
thereby preventing ATP binding, and leading to a loss in chaperone activity and
subsequent client protein degradation (87). A geldanamycin derivative, 17AAG, has
recently entered clinical trails for the treatment of cancer. 17AAG is an ATP-antagonist
that blocks p23 association with Hsp90, which destabilizes interactions with client
proteins, and induces proteasomal degradation. Since the Hsp90 oncogenic client
protein repertoire has been discovered, these inhibitors may combat oncogene
switching, which seems to be a critical mechanism of cancer cell survival (82). Targeting
chaperones and/or co-chaperones that regulate AR activity is another avenue to combat
the ever-evolving CRPC. However, understanding the unique environment in which
metastatic tumors thrive at the consequence of its host remains an area of much
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needed research.
1.3 ANDROGEN RECEPTOR SIGNALING PATHWAY
1.3.1 Androgen Receptor
The androgen receptor (AR) belongs to an important class of transcription factors
that regulate a diverse number of physiological functions, including control of embryonic
development, cell differentiation and homeostasis. This sub-family of steroid hormone
receptors includes glucocorticoid receptor (GR), progesterone receptor (PR), estrogen
receptor (ER) and mineralocorticoid receptor (MR). The AR gene is located on
chromosome Xq11-12 and spans 180 kD of DNA with eight known exons, encoding for
a protein that is structurally and functionally similar to other nuclear receptors. It exists
in two isoforms, AR-A and AR-B that are created by splice variants. AR-B is the fulllength form, 110kDa and AR-A is the truncated form, 87kDa, however, other truncated
variants are present in prostate cancer tissues. Here, I will focus on AR-B, which is
found predominantly in the cytoplasm and nucleus of the cell. AR-B functions as a dimer
in the nucleus to regulate the transcription of target genes in a ligand-responsive
manner. Its ligands, androgens, are sex hormones that belong to the steroid hormone
family. In gestation, testicular androgens are a necessary differentiation process that
leads to primary sex characteristics of males. AR has the greatest binding affinity
towards 5α-dihydrotestosterone (DHT) followed by testoterone, which dissociates from
the receptor more rapidly than DHT. The prototypical AR protein contains several
functional domains. An N-terminal transactivation domain (NTD), a highly conserved
DNA-binding domain (DBD) encoded by exons 2 and 3, a hinge region and a carboxyl
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terminal ligand binding domain (LBD) encoded by exons 4 to 8, as seen in Figure 1.1
(89,90 92).
The NH2-terminal domain (NTD), encoded by exon 1, constitutes more than 60%
of the AR protein, and is the least homologous in sequence between the steroid
hormone receptors. The NTD is a major transactivation domain, is structurally flexible,
and functions in multiple protein–protein interactions with co-regulatory proteins and
other components of the general transcription machinery. This region contains several
homopolymeric amino acid stretches, a polyglutamine region, nine proline residues and
24 glycine residues. It is thought that the polyglutimine and the nine prolines are
important in transcriptional regulation via its protein-protein interaction with other coregulators. AR transactivation is determined almost exclusively by the NTD (94). The
NTD interacts with the C-terminal domain (CTD) through a FQNLF motif, in an
intramolecular head-to-tail interaction, prompting gene expression (19). Deletion studies
show that there are several isolated transcriptional activation domains within the AR
NTD that act on transcription differently depending on cell lines and the use of different
promoters. These domains are known as, smaller activation function 1 and 5 (AF1 and
AF5) (95). The AF1 domain is located between residues 101-370 and is required for full
ligand activated transcriptional activity. The AF1 is an activation site and is thought to be
the major domain responsible for mediating AR transcriptional activity. AR, in addition to
GR, is unique in that most of its activities are mediated by the constitutive activity of AF1
(96). AR AF1 interacts with the large subunit of the general transcription factor TFIIF,
termed RAP74, and the steroid receptor co-activator 1 (SRC-1) (97). Co-activators alter
chromosome structure and can enhance or repress transcription activity by changing

14

the accessibility of the specified DNA region to the general transcription machinery. AF5
is located between residues 360-485 and is responsible for the constitutive activity
(activity without bound ligand). AF5 is comprised of three amino acid stretches: proline
stretches (371-378), an alanine stretch (397-401) and a glycine stretch (448-463).
Although very little is known about AF5, studies indicate that deletion of the ligand
binding domain, which results in the loss of AF1, induces the use of AF5. It has been
determined that elongated Gln repeats of more than 40 residues in this region is
associated with Kennedy’s disease (99). Furthermore, AR contains the small
ubiquitination like modifier (SUMO)ylation sites K386 and K520, that are thought to
repress gene transcription (98).
The DBD is a cysteine-rich region of AR made up of two zinc binding motifs and
has a loosely structured carboxyl terminal extension (CTE). This region is the most
conserved region among steroid hormone receptors (SHRs), displaying approximately
80% amino acid identity with MR, PR and GR, and is critical for the folding and function
of the domain. The first zinc finger interacts with the major grooves of the DNA termed
the P-box and is the recognition helix that interacts with transcriptional enhancers. The
second zinc finger interacts with the D-box, which is highly basic and stabilizes DNAreceptor interaction by contact with the DNA phosphate backbone and mediates
accurate receptor dimerization. Studies indicate that the receptor may not directly bind
to DNA, but piggyback onto other DNA-binging proteins such as the AP-1 heterodimer
components Fos and Jun. The CTE is also essential for response element recognition
and high affinity binding, specifically of the AR (100, 101).
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Figure 1.1: Domains of Steroid Hormone Receptors
Major domains are identified in color. The 3D structures show an illustration of the DBD
interacting with DNA and LBD interacting with ligand.
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The hinge region is a flexible linker located between the DBD and the LBD. It is poorly
conserved and contains a nuclear localization signal and export sequence, which is
critical for the transfer of AR from the cytoplasm to its site of action in the nucleus (21).
The hinge region also undergoes various post-translational modifications including
acetylation and phosphorylation. Acetylation of AR by p300/CBP-associated factor and
HIV-Tat interacting protein (Tip60) represses transcriptional activity through decreasing
activation of the receptor, nuclear transactivation and cofactor recruitment to the
promoter. Mitogen Activated Protein Kinase (MEK-K) also phosphorylates AR, which
assists in translocation (102, 19).
Finally the ligand-binding domain (LBD) shares a 50% identity with GR, MR, and
PR. The LBD functions to bind androgens with high affinity, it’s an interaction surface for
Hsp90, and dimerization of the receptor. When ligand binds, it induces a conformational
change of the last helix, which stimulates the transformation of a hydrophobic region
termed activation function 2 (AF2) for co-activator binding (103). Several co-activators
bind to this surface via the conserved LXXLL or FXXLF binding motifs to enhance the
transcriptional activity of the receptor (105, 106. The LBD has an internal binding site
that is comprised of 18 crucial residues located in helices 3, 5, and 11, known as
Binding Function 1 (BF1). Helix 12 operates as a gate on the ligand binding domain; it
opens to permit ligand binding and closes once ligand has bound (104). Recently
another co-activator binding site has been identified that is adjacent to AF2. It is thought
that this surface could be the site of protein-protein interaction for AR regulatory binding
proteins and has been termed binding function 3 (BF3) (103). Thus, the androgen
receptor is very tightly regulated, and mutations that comprise receptor structure and
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function can lead to the development of numerous diseases, including prostate cancer.
(15,16,17).
1.3.2 Steroid Hormone Receptor Complex
Steroid hormones (SH) are lipid-signaling molecules that are synthesized in the
adrenal cortex and gonads from cholesterol. Cholesterol is a soft, waxy, fatty compound
that is produced in the liver and further synthesized in mitochondria and smooth ER of
target organs. It is an important nutrient that is essential in the formation and
maintenance of cell membranes, and in the production of sex hormones. All steroid
hormones are derived from cholesterol and regulate a large number of physiological
processes in target cells. There are five major groups of steroid hormones: estradiol,
progestins, androgens, glucocorticoids, and mineralocorticoids. All steroids share a
carbon skeleton composed of four fused rings, a 3 six-member ring and 1 five-member
ring, at position C-17 there is a substitution that varies from hormone to hormone,
depending on desired function. ( 44, 108)
In order for steroidogenesis to occur the appropriate enzymes are necessary.
Enzymatic activities involved in androgen synthesis in the testis are mainly localized in
Leydig cells. Testosterone production is controlled by Lutenizing hormone (LH), which
regulates the expression of the enzyme 17-β hydroxysteroid dehydrogenase and
converts androstenedione to testosterone. Once cholesterol enters the Leydig cells and
is stimulated by LH the cholesterol is modified by an enzymatic cascade located in the
mitochondria and smooth endoplasmic reticulum (sER). Steroidgenic acute regulatory
proteins transport the cholesterol from the external membrane to the internal membrane
of the mitochondria where steroid hormone (SH) modification begins. First,
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CYP11A1/Demolase converts cholesterol to Pregnenolone. Pregnenolone can then
diverge into 3 different pathways depending on desired steroid hormone. The 2nd step
occurs in the sER in the case of androgens, pregnenolone is converted into 17hydroxypregnenolone by CYP17 or progesterone by 3-β-hydroxysteroid dehydrogenase
(3-β HSB). 3-β HSB is the only enzyme within this pathway that is not apart of the
cytochrome P450 family. 17-hydroxypregnenolone is further reduced by CYP17 to
dehydroeplandrosterone, which is then converted to Androstenedione by 3-β HSB.
Lastly, 17-β HSB converts androstenedione into testosterone, which is secreted into the
bloodstream where they are bound to carrier proteins, called sex hormone-binding
globulins. Androgens are lipophilic molecules that enter the target cells by simple
diffusion (8). Once in the cytosol, steroid hormones are cleaved by 5α-reductase and
other molecular modifications such as phosphorylation, which make them suitable
ligands to bind their appropriate steroid hormone receptor within the Steroid Hormone
Receptor Complex (SHRC) (8,9).
SHRs are key mediators of steroid hormone ligand action. All SHRs are
transcription factors that bind DNA and turn on gene expression, and are mainly found,
in the absence of hormone, in the cytoplasm in complex with chaperone proteins. These
receptors are constantly undergoing dynamic nucleocytoplasmic restructuring by
forming large oligomeric structures with one or more chaperones, co-chaperones and/or
co-activators known as regulatory proteins. Figure 1.2 illustrates the classic GR
maturation process. There are 3 stages of receptor maturation including early,
intermediate, and late folding events.
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Figure 1.2: Steroid Hormone Receptor Maturation Cycle
Figure 1.2 depicts a General Illustration of the Chaperone Mediated Receptor
Maturation Complex.
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At every stage the chaperones and co-chaperones associate and disassociate
with the receptor as it progresses to its high affinity hormone binding conformation. The
association of Hsp40 to the naïve receptor LBD characterizes the early complex, which
is a prerequisite for Hsp70 recruitment. Hsp40 initiates Hsp70’s ATPase activity,
permitting Hsp70 to form a direct interaction with the LBD. The intermediate complex
allows the association of Hsp Interacting Protein (HIP) and Hsp Organizing Protein
(HOP) or chaperone cofactors such as BAG-1 and CHIP with hsp70. When steroid
hormone receptors are improperly folded they are tagged with ubiqitin ligase (CHIP) and
are tagged for the proteasomal degradation pathway. HIP increases the stability of the
ADP-bound form of Hsp70 and Hop is a tetratricopeptide repeat (TPR)-containing
protein that acts as an adaptor protein promoting the transition from hsp70 to the hsp90
dimer. Once hop recruits the Hsp90 dimer, hsp70, Hip, and hop dissociate. At the
mature stage Hsp90 recruits the p23 cochaperone and one of a family of immunophilin
proteins (FKBP52, FKBP51, PP5 and Cyp40), resulting in a stable complex that is
capable of high affinity hormone binding (10,11). Hsp90 contains a nucleotide-binding
domain that acts as an ATP/ADP switch domain, regulating hsp90 confirmation. It
shows a higher affinity to hydrophobic substrates when bound by ADP, while the p23
bound form has more efficient chaperoning properties. p23 stabilizes the receptorhsp90 heterocomplex in an ATP-bound manner and is highly conserved between
animals, plants, and yeast. SHR localization to the nucleus is signified by a nuclear
localization signal (NLS) found in the hinge region and DBD of the steroid hormone
receptor. This region of the receptor is exposed once mature complex dissociates and
undergoes a conformational change releasing the Hsps. The receptor dimerizes, rapidly
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translocates to the nucleus and binds the appropriate hormone response element
(HRE). However, experimental evidence suggest another model for nuclear shuttling,
implicating the mature complex in nuclear translocation. It is thought that GRHsp90/p23/immunophilin transports the mature complex to the nucleus and also can
interact with the nuclear pore proteins, importin-β and Nup62 (107). Furthermore,
hormone binding of the SHR dimer modifies the secondary and tertiary structure of the
chromatin, which attracts other transcriptional cofactors such as p160, and p/CAF
(8,12). These cofactors facilitate further chromatin remodeling, making it conducive for
active gene transcription, thus, regulating the expression of hormone responsive genes.
Thus, disruption of SHR folding indirectly through changes in the components of the
SHRC could lead to devastating effects on the human reproductive system (infertility),
interfere with proper sexual development (androgen insensitivity) and contribute to
various cancers (breast and prostate cancer) (13,14,15).
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Figure 1.3: Hsp90 Client Proteins.
Illustration depicts various HSP90 Co-chaperone binding partners, varies Client protein
that rely on HSP90 activity and the multiple biological pathways HSP90 is involved.
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1.3.3 FK506 Binding Proteins
Immunophilins are a functionally diverse group of co-chaperones that are known
for their ability to bind immusuppressive drugs through the peptidyl-prolyl cis-trans
isomerase (PPIase) domain. Immunophilins are known for their PPIase enzymatic
activity, although, it is now known that PPIase activity is not involved in immune
responses or chaperone activity (108). PPIase enzymatic activity catalyzes the cis/trans
isomerization of peptidyl-prolyl, which affects the backbone arrangement of the target
protein (17, 18). Immunophilins can be separated into two major classes based on their
ability to bind immunosuppressive drugs. The first class is cyclophilins, which bind
cyclosporine and the second is FK506-binding proteins, which bind FK506, FK1706,
and rapamycin (18). FK506-binding proteins are the only class of proteins that will be
further discussed here. FK506-binding proteins (FKBPs) are a unique class of
immunophillins that perform many cellular functions including protein folding, regulation
of cytokines, nucleic acid binding, histone assembly, and modulation of apoptosis.
There are 15 FKBPs in humans and most of them possess numerous functional motifs
and FKBP domains such as: nucleic acid binding regions, TPR domains, calciumbinding

domains,

transmembrane

domains,

nuclear

localization

signals,

and

endoplasmic reticulum signal sequences. The diversity in these proteins enables them
to perform a wide variety of cellular functions, including protein folding. FKBP12 is the
most comprehensively studied and smallest (108 aa) of the FKBPs, containing only one
PPIase domain (18). FKBP12 is an ubiquitous, abundant protein that is a receptor for
rapamycin, which elicits its effects by binding to and inhibiting intracellular calcium
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release channels and the transforming growth factor β (TGF-β) type I receptor (21).
Many of the larger FKBPs are more complex, containing multiple protein-protein
interaction domains, and are involved in the regulation of high molecular weight
complexes including the SHRC.
1.3.4 FKBP51 and FKBP52
Human FKBP52 and FKBP51 are two large immunophilins that promote and
inhibit, respectively, the activity of AR, GR, and PR. FKBP51 and FKBP52 are
evolutionarily related Hsp90-binding co-chaperones, yet they have unique interaction
with Hsp90 and Hsp90 client proteins. Although Hsp90 binds many client proteins within
the SHRC, it recruits specific co-chaperones based on which client protein is bound.
Figure 3 shows an illustration of Hsp90’s many client proteins and TPR containing
proteins that participate and support Hsp90-client interactions. FKBP51 and FBP52
also have chaperoning activity that is independent of both Hsp90 and PPIase activity
(28). Hsp90 is the most abundant cytoplasmic chaperone involved in the stress
response and has a critical role in stabilizing proteins. Studies have shown that Hsp90
association is required for the normal activity of SHRs, and in SHRCs it is typically
bound to one of the large immunophilin co-chaperones including FKBP51, FKBP52,
Cyclophilin 40 (CyP40), or protein phosphatase 5 (PP5) (25). FKBP51 and FKBP52 are
composed of three distinct domains and are highly similar in sequence and structure as
seen in figure 1. 4. The FK1 domain consists of a functional PPIase active site, while
FK2 has a similar structure but differs at several amino acids that are critical for PPIase
activity and drug binding (22).
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Figure 1.4: Functional Domains of Human FKBP52.
FKBP52 has 3 distinct domains:FK1 domain: PPIase active site, FK2:PPIase like
domain, a TPR: Hsp90 interaction site.
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The FK2 domain also contains a consensus ATP/GTP-binding sequence
between amino acid 199 and 222. The region between FK1 and FK2 contains a hinge
linker region (FK loop) that is stabilized by extensive hydrogen bonds and hydrophobic
interaction on both FKBP51 and FKBP52. There is also a TEED functional sequence
between FK1 and FK2 that is phosphorylated by casein kinase 2, thereby preventing
binding of FKBP52 to Hsp90. Studies indicate that phosphorylation at this site
decreases FKBP52 potentiation of receptor activity. The corresponding sequence in
FKBP51 is FED, which lacks the consensus phosphorylation site. It is believed that this
mutation impacts the ability of FKBP52’s linker region to form hydrogen bonds properly
(6, 40). In addition, the FK2 domain in FKBP51 is thought to be brought into close
proximity to the receptor by Hsp90 for direct interaction with the receptor, and is
required for preferred binding to Hsp90-GR complex (29).
The third domain is composed of three TPR domains that interact with the Cterminal region of Hsp90 (24). The TPR motif contains six helixes, with a seventh helix
that extends beyond the core TPR domain. In FKBP51, the TPR domain projects at an
angle from the rest of the protein, but in FKBP52, the TPR domain extends linearly with
the rest of the protein. Hsp90 binding is mediated by electrostatic interactions between
the TPR motif and the highly conserved MEEVD motif in the extreme C-terminus of
Hsp90,,and by hydrophobic interactions with residues upstream of MEEVD. Studies
have determined that the hydrophobic interaction with the peptide is critical for
specificity (25, 26). FKBP51 exhibits ionic bonding between the FK2 and TPR domains,
whereas FKBP52 lacks these bonds and is therefore more flexible in nature (108).
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Figure 1.5: X-ray Crystallographic Structures of FKBP51 and FKBP52.
The three-dimensional structure of the composite of two partial structures for human
FKBP52 (protein databank: 1Q1C and 1P5Q) and the structure of human FKBP51
(protein databank: 1KT0) are shown in ribbon format. The important functional regions
FK1 (red), FK2 (orange), TPR (yellow), and the proline loop (Green), are illustrated. The
figure was created using UCSF Chimera version 1.5.
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In addition molecular studies indicate that FKBP51 and FKBP52 may augment
receptors by different mechanisms. They both bind Hsp90 differently, FKBP52 only
interacts through the TPR domain, but FKBP51 requires additional sequences up and
downstream of the TPR domain (109). The forth domain, unique to FKBP52, is a
putative binding site for calmodulin. While FKBP52 does not associate with calcineurin,
an FKBP52 K121L mutant has high affinity for calcineurin (27).
Although similar in structure and sequence, FKBP51 and FKBP52 functionally
diverged in their ability to regulate steroid hormone receptor activity. Both in vitro and in
vivo studies show that FKBP52 positively regulates AR, GR, and PR signaling pathways
(28, 30, 31). While FKBP51 does not inhibit hormone receptor activity in yeast, it can
block the potentiation mediated by FKBP52 when co-expressed (6). FKBP52 has a
distinct functional influence on the AR and PR signaling pathways, is critical for proper
development of vital male reproductive organs, and may play a critical role in male and
female fertility.
The physiological importance of FKBP52 was demonstrated through the use of
FKBP52 knockout mice (52KO). The 52KO male mice had reproductive phenotypes
including infertility, abnormal external virilization, ambiguous external genitalia, and
dysgenic seminal vesicles and prostate, which can all be attributed to the loss of steroid
receptor activity. The physiological/developmental abnormalities of the 52KO mice
parallel those of human pathologies seen in AIS, which is linked to the desensitization of
AR. Studies done in New World Primate also demonstrate that reduced expression of
FKBP52 is associated with androgen insensitivity syndrome. Liquid chromatographytandem mass spectrometry analysis found that serum derived from squirrel monkeys
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had very high levels of androgenic hormones during breeding and non-breeding
seasons when compared to humans. Dihydrotestosterone (DHT) levels in squirrel
monkeys can reach 4.8 +/- 0.7 verses 0.33 +/- 0.01 in humans. Western blot analysis
demonstrated that FKBP51 is higher and FKBP52 is lower in squirrel monkeys, which
was thought to be a probable cause of reduced AR activity. Squirrel Monkey FKBP51
had no effect on DHT-stimulated AR activity. However, the overexpression of FKBP52
resulted in a significant increase in reporter activity. Therefore, researchers concluded
that low androgen responsiveness in squirrel monkeys is the result of low FKBP52
expression (32).
Although the female 52KO mice had no morphological abnormalities, they were
completely infertile. This infertility was due to maternal failure of embryonic implantation
and decidualization; both processes are stimulated by, and dependent on, progesterone
receptor activity. Interestingly, no defects in male and female physiology were seen in
FKBP51 knockout mice, suggesting that FKBP51 is not necessary for AR activity in
vivo. (33). However, the loss of both FKBP51 and FKBP52 in mice results in embryonic
lethality. Thus, FKBP52 plays an indispensable physiological role, which cannot be
substituted by the presence of other homologous proteins (28).
Additional cellular and yeast studies continue to substantiate FKBP52’s role in
AR signaling. FKBP52 is thought to have various functional roles within the AR signaling
pathway. There is evidence that FKBP52 enhances receptor transcriptional activity by
increasing the receptor’s affinity for androgen, mediated by conformational changes
within the AR ligand-binding domain (23,24). Studies also suggest that FKBP52 may
influence the receptor’s movement to the nucleus because FKBP52 is a regulator of
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microtubules and associates with the dynein motor protein, thereby regulating SHR
translocation to the nucleus (34, 35). This is still unclear as another study (Baulieu) has
shown that FKBP52 promotes microtubule disassembly, which is a direct contradiction
to this theory. FKBP52 does interact with dynein and this may be a functional interaction
that is important for sperm motility (flagellar motor proteins) as the 52KO mice have
defects in sperm motility. However, this may have nothing to do with SHRs as sperm
motility is not an androgen-dependent process. It has also been noted that FKBP52 is
not required for AR to be competent for hormone binding (28,6). Though FKBP52 is not
required for hormone binding, research has consistently shown that FKBP52 has the
ability to up-regulate AR signaling 20-fold, in comparison to other closely related
immunophilins such as FKBP51, Cyp40, and PP5 (6). This strongly supports a role for
FKBP52 in reproductive development in both male and female mice. However, the
mechanism by which FKBP52 modulates receptor expression is not well understood.
The evidence discussed above, and other recent findings implicating a role for FKBP52
in androgen insensitivity, infertility, and prostate cancer, has lead researchers on a
quest to better understand the significance of FKBP52 within the steroid hormone
receptor signaling pathway (8,11,28,36).
FKBP51 was discovered as a component of chicken PR complexes and is an
Hsp90 co- chaperone within the SHRC. FKBP51 inhibitory effects were initially
characterized in New World primates. The insensitivity to glucocorticoids and progestins
in New World primates has been linked to the overexpression of FKBP51.
Human FKBP51 inhibits both receptors’ function. Mapping studies have shown that
amino acid changes increase inhibitory actions of squirrel monkey FKBP51 (32).
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FKBP51 has not been fully characterized in the SHRC, but in vitro studies show that
FKBP51 inhibits SHR function through competition with FKBP52 for binding Hsp90. On
the other hand, other Hsp90-binding TPR proteins do not block FKBP52 action as
compared to FKBP51, so FKBP51 inhibition of SHR activity may not be through simple
competitive inhibition of FKBP52 regulation.
Researchers have established that there are distinct functional differences
between FKBP51 and FKBP52 within the SHRC. However, the underlying structural
and functional relationship between the two proteins has only recently been thoroughly
investigated. Sequence analysis of FKBP51 and FKBP52 shows that FKBP51 has 70%
amino acid sequence similarity to FKBP52. Crystal structure analysis also shows an
almost identical conformation within the structural domains. An additional study utilized
Threading/ASSEmbly/Refinement approach (a protein tertiary structure prediction
algorithm) to analyze FKBP51 and FKBP52 structure. This study showed that they
possess the same structural arrangement consisting of two FKBP domains and 3-4
pairs of helical TPR motifs, with the FKBP domains rotating approximately 90 degrees
about a 10-residue loop. Structural analysis also determined that there is an apparent
distinction in FKBP51 and FKBP52 domains, particularly within the FK2 and TPR
domains. The FKBP52 TPR domains are aligned in a more linear orientation, while the
TPR motifis of FKBP51 are packed more closely to the FK2 domains, giving it a kinked
confirmation, which could account for FKBP51’s higher affinity for hsp90 binding (18,
28). FKBP51 contains a side chain that forms a salt bridge between the FK2 and TPR
domains that stabilizes the interaction between its domains. Though FKBP52 lacks this
salt bridge, it could contribute to the flexible structure of FKBP52, which may be
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responsible for it interactions with more SHRs (38, 39).
FKBP52 mutagenesis studies have discovered several critical structural
differences between FKBP51 and FKBP52, which are related to their function. The
FKBP52-K354A mutation abolishes FKBP52 binding to Hsp90 and FKBP52 potentiation
of receptor activity. Additional truncation mutants were generated to investigate whether
the TPR domain is sufficient for potentiation of GR activity. Studies showed that all
truncated FKBP52 mutants lacked the ability to potentiate receptor activity, which
indicates that the TPR domain is not sufficient for FKBP52 potentiation. However,
Hsp90 remains a critical binding partner allowing FKBP52-receptor interaction (23). In
domain swapping experiments chimera constructs were generated in which the
FKBP52’s FK1 domain was exchanged. FKBP52 substituted with FKBP51 FK1 domain
greatly decreased FKBP52-mediated enhancement of receptor activity. Interestingly,
the converse substitution on FKBP51 caused a gain in potentiation, however it was only
50% the activity seen with FKBP52. (23) This suggests that the FK1 domain is
important for FKBP52 function, yet other unidentified domains/regions still remain.
Mutagenesis studies demonstrated that the FK2 domain may contain an interaction site
that may confer FKBP51 and FKBP52 ability to identify a specific interaction partner,
such as steroid hormone receptors. A gain-of-function random mutagenesis of FKBP51
generated

an

FKBP51

mutant

that

could

potentiate

receptor

activity.

The

characterization of these mutants uncovered a proline-rich loop region that overhangs
the PPIase catalytic pocket in the FK1 domain, which is critical for FKBP52’s function.
This loop contains several critical prolines at position 119 and 124 in FKBP52; the
corresponding positions in FKBP51 are leucine and serine. Although the FKBP52
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proline-rich loop is critical, mutations that make the FKBP52 loop more like that of
FKBP51 only reduced receptor activity approximately 40%. Therefore, researchers
concluded that there are additional unidentified regions or residues in FKBP52 that are
essential for full function (16).
1.4 CURRENT RESEARCH FOCUS
Our lab is continuing to develop inhibitors specific to FKBP52, which is thought to
bind the BF-3 region of the AR, thus augmenting its activity (110). Studies are currently
being conducted to design inhibitors that specifically target FKBP52 regulation of the
receptor through further characterization of its functional domains. A compound,
MJC13, is predicted to bind to the BF3 surface (FKBP52 interaction site) that impairs
the dissociation of the AR-Hsp90-hFKBP52 complex, resulting in an inhibition of AR
nuclear translocation and AR dependent gene expression (110). As it stands current
research has been limited in their capacity to specifically target AR: h52 interaction. In
pursuit of this novel mechanism for targeting AR mediated gene expression further
investigation into h52 structural and functional domains and residues is of vital
importance.
Comparative analysis is a very powerful tool in research science. A select gene
is compared with orthologous gene, allowing researcher to identify structural and
functional domains, which was previously done using FKBP51. This study will be using
an evolutionarily similar protein, Danio rerio FKBP52 (DrFKBP52), for a comparative
analysis to help in understanding the relevant sequence differences that distinguish
their ability to potentiate steroid hormone receptors. Danio rerio has been used in the
past as an important vertebrate model organism in scientific research, the protein
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DrFKBP52 activity within the steroid hormone complex is undocumented in current
literature. Like h52, DrFKBP52 contains the 3 distinct domains: FK1, FK2, and a TPR
domain. DrFKBP52 FK1 domain is comprised of the 9 amino acids that comprise the
proline-rich loop. Its FK linker region, that connect the FK1 and FK2 domains contains a
consensus casein kinase II (CKII) phosphorylation site, box outline (111). The FK2
domain is 85% conserved between DrFKBP52 and hFKBP52, and it also lacks an
active PPIase domain. Both also contain the motif that binds HSP90 (2003). Despite
their similarity at the amino acid level and structural level, DrFKBP52 and hFKBP52 are
functionally divergent. Our thorough assessment of DrFKBP52 has led us to the
conclusion that it would be an excellent model protein for gain-of-function comparative
analysis with hFKBP52.
1.5 DISSERTATION GOAL
Because FKBP52 has an integral role in androgen receptor regulation and male
sexual development, our lab is investigating it as a possible therapeutic target to treat
Androgen-dependent and -independent diseases such as PC. Although previous
research has identified several critical residues that are important for FKBP52 function,
we hypothesize that the FKBP52 FK1 and FK2 domains contain additional regions
and/or residues required for function within the steroid hormone receptor
complex. While Danio rerio (zebrafish) FKBP52 (Dr52) possesses all known residues,
regions, and domains known to be critical for FKBP52 function, Dr52 lacks the ability to
potentiate receptor activity. We aim to further characterize functional regions through
cross-species comparison with DrFKBP52 and human FKBP52 (h52), and to perform a
gain-of-function random mutagenesis screen of Dr52 (6,40). Cross-species comparison
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between two similar proteins with distinct functions has been used as a powerful tool in
research. This approach will allow us to further map out and characterize functional
regions important for FKBP52’s full function. The overall goal of this work is to further
delineate functional regions in hFKBP52 that are critical for its function and characterize
AR-h52 interaction sites, which will ultimately serve as therapeutic drug targets
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CHAPTER 2: FUNCTIONAL AND STRUCTURAL COMPARISON OF
HUMAN AND DANIO RERIO FKBP52 REVEALS A NOVEL DOMAIN
IMPORTANT FOR hFKBP52 FUNCTION
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2.1 RATIONALE
Current literature has established FKBP52 as a critical player in the
development and integrity of the male reproductive system and male phenotype (3).
This, along with other recent developments, implicates FKBP52 as a relevant factor in
PC, AIS, and endometriosis, which makes FKBP52 an attractive therapeutic target.
Biochemical

and cellular studies demonstrated that FKBP52 potentiates steroid

hormone receptor signaling pathways. As we seek to target AR-FKBP52 interactions as
a novel approach to PC therapy, determining functional domains (i.e. potential drug
binding sites) has become increasingly important in developing FKBP52 specific
inhibitors. Prior to this study, Riggs et. al (6). identified a proline-rich loop region, which
overhangs the catalytic PPIase pocket, that is thought to be important for FKBP52
functional activity and interaction with AR. This loop was identified through a random
mutagenesis screen of FKBP51; a protein that is 70% similar to FKBP52, but that does
not potentiate receptor function. Although this region is critical for FKBP52 function,
further investigation indicates that other residues may also contribute to FKBP52
function. This idea is reinforced by the fact that mutations which make the FKBP52
proline-rich loop more like that of FKBP51 only reduce FKBP52 activity by
approximately 40%. Thus, our initial hypothesis was that additional important
residues remain to be identified in the FKBP52 FK1 and/or FK2 domains. To
investigate this hypothesis, we performed a cross-species comparison with other FKBP
proteins, created chimera constructs using DrFKBP52 and hFKBP52, evaluated the
chimeric proteins’ function in yeast-based assays, assessed the chimeric proteins for
the ability to associate with Hsp90, and corroborated our results in a higher vertebrate
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model system (52KO mouse embryonic fibroblasts). This approach allowed the further
mapping and characterization of functional regions that are critical for FKBP52 function
within the SHRC.
2.2 MATERIALS AND METHODS

2.2.1 Construction of FKBP52 And DrFKBP52 Chimeras
For the HZ-96 and ZH-262 chimeras, chimeric cDNAs combining hFKBP52 and
DrFKBP52 cDNA sequences were constructed by PCR. Primers for the two fragments
were designed to contain the complementary sequences that surround the desired
fusion site. The resulting DNA products are gel-purified and used as megaprimers in a
reaction with the appropriate 5’ - 3’ primers to generate the full-length chimeric cDNA.
The final PCR product was ligated into pSPUTK (Stratagene) for in vitro expression, or
into a yeast expression vector.
For the HZ-139, HZ-258, and ZHZ-150_250 chimeras, chimeric cDNAs
combining hFKBP52 and DrFKBP52 cDNA sequences were constructed by yeast
recombination method. Yeast has the unique ability to recombine any template that has
homologous overlapping regions when co-transformed with another template or
linearized vector containing the homologous regions. Primers for the appropriate
fragments were designed to contain the complementary sequences that surround the
desired fusion site. Fragment templates were PCR amplified with desired overlapping
regions homologous to the fusion site, the PCR product was gel purified and quantified.
Double or single digestions were performed on DrFKBP52 and hFKBP52 in the desired
cloning region, the reactions were gel purified and quantified. The amplified fragment
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and linearized plasmid were co-transformed into yeast (W303a) in a 1:10 ratio.
Transformed yeast were streaked on selective media plates and incubated at 30°C for 4
days. Several colonies were picked from the plate and cultured overnight in appropriate
selective media. Plasmids were then extracted from yeast using standard procedures
and sequenced to verify correct construction of the chimeras.
2.2.2 In Vitro Protein Binding Assays
Radiolabeled

chimeric

proteins

were

generated

by

in

vitro

transcription/translation (TNT kit, Promega, Madison, WI) in the presence of [35S]methionine. A 5 µl aliquot of each synthesis mixture was separated by SDS- PAGE,
followed by autoradiography. Protein bands were quantified by densitometry. For each
Co-immunoprecipitation, molar equivalents of each radiolabeled protein was added to
100 µl of rabbit reticulocyte lysate (RL) (1:1 lysate; Green Hectares, Oregon, WI)
supplemented with an ATP-regenerating system. The RL mixture was added to the
immunoresin (a 10 µl pellet pre-adsorbed with 40 µg of Hsp90 antibody) and incubated
for 90 min at 30°C. Washed, resin-bound complexes were separated by SDS-PAGE,
Coomassie-stained, and autoradiographed.
2.2.3 Yeast Assays for Hormone-Induced Reporter Gene Expression
β-galactosidase reporter assays were used as a quantitative indicator of steroid
hormone receptor activity. Parental strains were co-transformed with three plasmids: a
constitutive receptor expression plasmid (p415GPD-GR, p425GPD-hAR, or p425GPDhAR-P723S), a hormone-inducible β-galactosidase reporter plasmid (pUCΔS-26x), and
a plasmid constitutively expressing a chimera variant. Isolates were cultured at 30°C
overnight (12-16 hours) in 5 mls of selective media (SC-LUW). Overnight cultures were
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diluted back to an optical density at 600 nm (OD600) of 0.08,and growth was monitored
by spectrophotometry for 30-60 min before hormone addition to ensure that the cultures
were in exponential phase growth. Deoxycorticosterone (DOC) or Dihydrotestosterone
(DHT) were added to the culture at 0, 100, and 500 nM and 0, 3, 5, and 10 nM final
concentrations respectively. To assay for galactosidase activity 100 µl of culture was
withdrawn and immediately added to 100 µl of the Gal-ScreenTM substrate (Applied
Biosystems, Bedford, MA) in 96-well microtiter plates at room temperature. One sample
is taken from each assayed isolate 120 min after hormone addition and read in a
luminometer. To determine the degree of reporter expression, galactosidase induction
curves were first generated by plotting relative light units (RLU) against the absorbance
at 600 nm of the culture. The normalized levels of reporter expression are reported
(OD600/RLU) and are all normalized to 100% expression. Data is represented as the
mean (+/- standard deviation) of at least three replicate samples.
2.2.4 Western Blot of Yeast Lysates
Yeast cells in exponential phase growth (OD600 approximately equal to 1) were
pelleted, washed in 1ml of lysis buffer, and then resuspended in 5 mls lysis buffer (20
mM Tris pH 7.5, 100 mM NaCl, 5% glycerol supplemented with protease inhibitors), and
vortexed vigorously in the presence of glass beads for 8 x 2 min. Cell extracts were
clarified at 14,000 rpm for 20 min at 4°C. Protein concentrations in yeast extracts were
determined using Coomassie Plus (Pierce, Rockford, IL). Typically, 20 µg of total
cellular protein per lane was separated on a 10-20% Criterion gel (BioRad, Hercules,
CA) and transferred to PVDF membranes. Mouse monoclonal antibodies Hi52D, Hi52B
were used to detect hFKBP52 and DrFKBP52, respectively.
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As protein loading

controls, yeast extracts were blotted with antibody recognizing the L3 ribosomal subunit
(housekeeping gene). The secondary antibody was an alkaline phosphatase-conjugated
goat anti-mouse antibody (Pierce, Rockford, IL), and bands were visualized with
Immun-Star AP Substrate (BioRad, Hercules, CA) and expose to X-Ray film.
2.3 RESULTS
2.3.1

Danio

rerio

FKBP52:

A

Comparative

Model

for

Human

FKBP52

Characterization
Our current knowledge of the characteristics that contribute to FKBP52
potentiation of receptor activity was thought to be predominately governed by the
proline-rich loop region that overhangs the PPIase catalytic pocket. Previous studies
corroborate the importance of this domain in a gain-of-potentiation random mutagenesis
screen performed on FKBP51 (6). However, chimeric studies with FKBP51 and FKBP52
suggest that additional residues may exist within hFKBP52, particularly in the FK2
domain, that are critical for function. Thus, we decided to do a cross-species
comparison of

hFKBP52

with

ten

other species

of

FKBP52

and

hFKBP51,

using clustalW alignment software, focusing close attention on the proline-rich loop
region (Table 2.1). Of these species, we observed that DrFKBP52 is approximately 61%
similar in amino acid sequence to hFKBP52. Upon further investigation it
was discovered that DrFKBP52 contains all of the regions and residues identified by
previous studies as critical for hFKBP52 function: proline rich loop and residues critical
for binding Hsp90 (Figure 2.1). Although Danio rerio has been used in the past as
an important vertebrate model organism in scientific research, DrFKBP52 function
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within the steroid hormone receptor heterocomplex is undocumented in the current
literature. Like hFKBP52, DrFKBP52 contains the three distinct domains, FK1, FK2, and
TPR domains, highlighted in grey in figures 2.1 and 2.2. The DrFKBP52 FK1 domain
contains the 6 amino acids that comprise the proline-rich loop.
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Table 2.1: ClustalW2 Alignment of FKBP Species
FKBP52

Gene bank#

P-Loop

CKII

Macaca mulatta
Mus musculus
Oryctolagus cuniculus
Rattus norvegicus
Mus musculus
Equus caballus
Monodelphis
domestica
Gallus gallus
Danio rerio
hFKBP51
Echinococcus
granulosus

NP_001248268
AAH03447.1
NP_001075779
EDM01775.1
AAH03447.1
XP_005610895
XP_001366229

Y
Y
Y
Y
Y
Y
Y

Y
Y
Y
Y
Y
Y
Y

Y
Y
Y
Y
Y
Y
Y

93.3%
89.96%
91.27%
90.17%
89.96%
87.58%
81.05%

459
612
458
560
612
414
462

Y
Y
Y
Y
Y
UNKNOWN
UNKNOWN

NP_001006250.1
AAI65584.1
AAH42605.1
CDJ23395

Y
Y
N
N

Y
Y
N
N

Y
Y
Y
N

74.66%
61.02%
54.7%
29.86%

442
449
448
432

Y
N
N
UNKNOWN
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HSP90
(YANMF)

%Homology

#Amino
Acids

Functional

Sequence Alignment
hFKBP52
DrFKBP52
hFKBP52
DrFKBP52
hFKBP52
DrFKBP52
hFKBP52
DrFKBP52
hFKBP52
DrFKBP52
hFKBP52
DrFKBP52
hFKBP52
DrFKBP52
hFKBP52
DrFKBP52

MTAEEMKATESGAQSAPLPMEGVDISPKQDEGVLKVIKREGTGTEMPMIGDRVFVHYTGW
MTAEEVVN-----EGCSIPIEGEDITPKKDGGVLKLVKKEGTGTELPMIGDKVFVHYVGT
*****:
:...:*:** **:**:* ****::*:******:*****:*****.*_
_
_
LLDGTKFDSSLDRKDKFSFDLGKGEVIKAWDIAIATMKVGEVCHITCKPEYAYGSAGSPP
LLDGSQFDSSRDRGEKFSFELGKGQVIKAWDIGVATMKIGEICQLTCKPEYAYGAAGSPP
****::**** ** :****:****:*******.:****:**:*::*********:*****
_
_
KIPPNATLVFEVELFEFKGEDLTEEEDGGIIRRIQTRGEGYAKPNEGAIVEVALEGYYKD
KIPPNATLLFQVELFDFRGEDITDDEDGGITRRIITKGEGYTKPNEGATVEVWLEGSHED
********:*:****:*:***:*::*****_***_*:****:****** *** *** ::*
_
_
KLFDQRELRFEIGEGENLDLPYGLERAIQRMEKGEHSIVYLKPSYAFGSVGKEKFQIPPN
RVFDERELKFEVGDGENLGLPLGVEKALQAMEQGEEALFTIKPKYGFGTAGSEKYNIPPN
::**:***:**:*:****.** *:*:*:* **:**.::. :**.*.**:.*.**::****
_
_
AELKYELHLKSFEKAKESWEMNSEEKLEQSTIVKERGTVYFKEGKYKQALLQYKKIVSWL
ATLQYKIKMKAFEKAKESWEMNTIEKLEQSVIVKEKGTQYFKEGKYKQAIVQYKRIVSWL
* *:*::::*:***********: ******.****:** **********::***:*****
_
_
EYESSFSNEEAQKAQALRLASHLNLAMCHLKLQAFSAAIESCNKALELDSNNEKGLFRRG
EHESSMQPDDEEKAKALRLAAYLNLAMCYLKLQDANPALENCDKALELDANNEKALFRRG
*:***:. :: :**:*****::******:**** ..*:*.*:******:****.*****
_
_
EAHLAVNDFELARADFQKVLQLYPNNKAAKTQLAVCQQRIRRQLAREKKLYANMFERLAE
EALVVMKEFDMAKVDFQRVIELYPANKAAKSQISICQKHMREQHEKDKRLYANMFQKFAE
** :.:::*::*:.***:*::*** *****:*:::**:::*.* ::*:******:::**
EENKAKAEASSGDHPTDTEMKEEQKSNTAGSQSQVETEA 459 Required for
RDAKEADQEKEQDKKQNGSAMEIDEN-----AAQEQTAA 449 Potentiation

FK1

120
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180
175

FK2
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300
295

TPR

360
355
420
415

hFKBP52
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Proline-rich
Loop

++

++
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++

+

CKII
-

++
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Figure 2.1: Sequence Alignment of hFKBP52 and DrFKBP52.
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Figure 2.1: Sequence Alignment of hFKBP52 and DrFKBP52.
ClustalW2 alignment tool was used to align hFKBP52 and DrFKBP52. Dr52 is ~61%
homology to hFKBP52. Identified in gray are the 3 major domains: FK1, FK2, and TPR
domains. Highlighted in yellow are the previously characterized critical domains:
Proline-rich loop and conserved residue indicative of Hsp90 binding. Boxed in black is
the CKII phosphorylation site. In the right corner is a table indicating comparative
activity relative to domains.
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FK1
(PPIase)
FK2
TPR
(Hsp90 Binding)
DrFKBP52

hFKBP52
Figure 2.2: 3D Crystal Structure of hFKBP52 and DrFKBP52.

The three-dimensional structure of the composite of two partial structures for human
FKBP52 (protein databank: 1Q1C and 1P5Q) and the structure of human DrFKBP52
(Homology modeling) are shown in ribbon format. The important functional regions FK1
(red), FK2 (orange), TPR (yellow), Blue is the FK1 linker and the proline loop (Green),
are illustrated. The figure was created using UCSF Chimera version 1.5.
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The FK linker region that connects the FK1 and FK2 domains contains a
consensus casein kinase II (CKII) phosphorylation site (TEEED, TDDED) (108, 111)
The FK2 domain is 85% conserved between DrFKBP52 and hFKBP52, and lacks an
active PPIase active site. Both contain a conserved motif, YANMF, that binds Hsp90
(24). In addition, we have superimposed the FK1 and FK2 domains of DrFKBP52 and
hFKBP52 and they have a high degree of similarity, and adopt a similar conformational
fold (Figure 2.3). Despite their similarity at the amino acid and structural level,
DrFKBP52 and hFKBP52 are functionally divergent (Figure 2.4). A functional yeast
assay reveals that DrFKBP52 does not confer the ability to potentiate human AR or GR,
like hFKBP52 as receptor activity in the presence of a plasmid expressing DrFKBP52 is
comparable to that in the presence of the empty vector control (Figure 2.3). Riggs et. al.
identified the highly conserved proline-rich loop region as being critical for hFKBP52
activity (6), and, although DrFKBP52 has a similar proline-rich loop, it does not have the
ability to augment receptor activity. Hsp90 binding studies show that DrFKBP52 has the
ability to bind Hsp90, yet at a decreased affinity (Figure 2.5). It must be noted that
preferred binding of hsp90 is not an accurate indicator of a protein’s ability to potentiate
receptor activity. This is seen in the preferential binding of FKBP51 to hsp90, yet
FKBP52 has a reduced affinity for Hsp90 (24). Based on these data, DrFKBP52 is a
highly similar protein to hFKBP52, yet lacks function. Thus, DrFKBP52 can serve as an
excellent model for comparative analysis with hFKBP52.
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Figure 2.3: Danio rerio and Human FKBP52 FK1 and FK2 Domains Superimposed.
The DrFKBP52 (orange) and hFKBP52 (blue) 3D crystal structure were superimposed
to identify structural similarities and differences.
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Figure 2.4: Functional AR and GR Yeast Assay of Danio rerio FKBP52
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Figure 2.4: Functional AR and GR Yeast Assay of Danio rerio FKBP52
Vector, FKBP52, FKBP51 and Dr52 were co-transformed into wt-AR or GR. Cells were
incubated for 2 hours with 3nM DHT or 500nM DOC. Three isolates were picked form
each strain and was replicated at least 3 times. AR and GR expression was measured
by evaluating reporter expression/relative light units (RLU), followed by a normalizing
with the final OD600 reading of cultured isolates. Bars represent the average reporter
expression of a least 3 replicates (RLU/OD 600 with SD).
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Figure 2.5: Hsp90 Binding FKBPs
(A) Co-IP of hFKBP52, hFKBP51, DrFKBP52 with HSP90. Pr22 is anti-PR and is used
as a non-specific binding control. Hsp90 was immunoprecipitated with radiolabeled (35Smethionine) hFKBP52, hFKBP51 and DrFKBP52. Proteins were separated by SDSPAGE, coomassie-stained, and autoradiographed (B) Input: loading control.
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2.3.2 Functional Assessment Of Chimera Constructs In Yeast And Mammalian
Cells
To further characterize the role of individual FKBP52 domains in the functional
maturation of steroid hormone receptors we created hFKBP52 and DrFKBP52 chimeras
by

interchanging

the

FK1,

FK2

and

TPR

domains.

We

generated

five

hFKBP52/DrFKBP52 chimeras and evaluated their functional relevance in yeast. These
chimeras were designed and generated through various experimental techniques: mega
primer PCR, PCR, Yeast recombination and fusion cloning. Each chimera was
meticulously constructed and sequence analysis was performed to verify the correct
sequence. The chimeras were transformed into three different yeast strains that express
a variety of receptors and their respective β-galactosidase reporter plasmids including
wild type AR (Figure 2.6B), GR (Figure 2.6C), or AR P723S (Figure 2.6E). The ability of
the chimeric proteins to potentiate receptor function was assessed by hormone-induced
reporter assays.
We first evaluated the relevance of the hFKBP52 TPR domain, Chimera HZ-262,
in the regulation of the steroid hormone receptors. Though TPR domains are highly
conserved across species, there is a possibility that it plays a role in structural integrity,
or has a specific interaction with the FK1 or FK2 domain given that the DrFKBP52 tail is
notably more kinked than that of hFKBP52.
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Figure 2.6: Functional Analysis of FKBP Chimeras.
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Figure 2.6: Functional Analysis of FKBP Chimeras.
(A) As diagrammed at the top of the figure, chimeric proteins were generated by
exchanging FK1, FK2 and TPR domains between DrFKBP52 (Dr52) (shaded) and
hFKBP52 (52) (white). The activities and expression levels of the FKBP constructs were
assayed in yeast containing (B) wt-AR, (C) AR:P723S or (D) GR. (E) Chimera
constructs activity was also assessed in 52KO MEF containing wild-type AR and an
appropriate hormone-dependent reporter. Chimeras were detected in cell extracts by
Western immunostaining with monoclonal antibodies specific for either the FKBP52 FK1
domain (Hi52B). Bars represent the average reporter expression of a least 3 replicates
(RLU/OD 600 with SD). Using the one way Anova statistical analysis following a post
turkey test with an alpha value of 0.05, AR, GR, AR:P7233 reporter activity is
significantly enhanced in cells transfected with Chimera ZHZ-150_250 and Chimera HZ262 as compared to those transformed with either Dr52 and HZ-139 when comparing
cells enhanced with DHT, with a p-value < 0.01. AR reporter activity is also significantly
enhanced in 52KO MEF cells transfected with Chimera ZHZ-150_250 as compared to
those transfected with either Dr52 and HZ-139 when comparing cells enhanced with
DHT, with a p- value < 0.001.
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Chimeras containing the hFKBP52 FK1/FK2 and DrFKBP52 TPR domains retains the
greatest ability to potentiate all receptors, demonstrating that the TPR domain is
conserved and functionally interchangeable. This fact was further established given that
Chimera ZH-258 (DrFKBP52:FK1/FK2 and hFKBP52:TPR) activity is comparable to
vector (Figure 2.6). Because the hFKBP52 FK1 domain has been identified as the main
contributor to receptor activity we assessed its function in combination with DrFKBP52.
FK1 has also been predicted to be the domain that contacts the BF3 surface on AR.
Surprisingly, Chimera HZ-139 (hFKBP52:FK1 and DrFKBP52: FK2/TPR) was unable to
potentiate receptor activity like hFKBP52. Because hFKBP52’s FK2 domain is a poorly
understood domain and has been previously identified as a non-functional domain, we
sought to determine its significance in hFKBP52 activity. DrFKBP52 and hFKBP52 are
approximately 85% similar in amino acid sequence identity. However, Chimera ZHZ150_253 (DrFKBP52: FK1/TPR and hFKBP52:FK2) has a statistically significant
increase in activity in AR and GR, as compared to DrFKBP52. In comparison with HZ139 that retains the FK1 domain, chimera ZHZ-150_253 has a marked improvement in
receptor potentiation. The FK2 domain has thus far been characterized as a redundant
domain with no identifiable significance, but these data identified a potential role for the
hFKBP52 FK2 domain. A functional yeast assay using AR-P723S was also done to
further solidify chimera functional relevance, as AR- P723S is hyperdependent on
hFKBP52 for activity. Results substantiate chimera HZ-262 role in restoring receptor
function like hFKBP52. Chimera ZHZ-150_253 restores partial receptor activity, while
chimera HZ-139 could not. Yeast data was corroborated in 52KO mouse embryonic
fibroblast cells, which further corroborates the previous data. Collectively this data gives
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us new insight into the role of the FKBP52 FK2 domain in receptor modulation and
could be a possible target for FKBP52 specific inhibitors (Figure 2.6).
2.3.3 Characterization of the FK2 Domain
Our pervious data clearly indicate hFKBP52 FK2 domain as a regulator of steroid
hormone receptor activity. This discovery has led us to evaluate whether specific
residues can be identified in the FK2 domain that specifically contribute to hFKBP52’s
ability to modulate receptor function. In an effort to isolate critical residues in the FK2
domain we have done a comparative analysis of DrFKBP52, hFKBP52, and hFKBP51.
It has been determined that the divergent factor between hFKBP52 and hKBP51 is the
proline-rich loop region, suggesting that the important residues in the FK2 domain are
likely the same in hFKBP51 and hFKBP52. We have utilized this fact in identifying
residues that differ in DrFKBP52 as compared to both hFKBP52 and hFKBP51. We
mutated residues in DrFKBP52 in hopes that it would restore its ability to augment
receptor activity. Using this comparative approach we identified 8 residues that are not
conserved between DrFKBP52 and hFKBP52 (Figure 2.6). This rational approach
allowed us to identifying possible important residues. Residues were identified and sitedirected mutagenesis was preformed to mutate residues on DrFKBP52. These mutants
were co-transformed with wild type AR and yeast assays were preformed to determine
functional significance. Results indicated that none of the mutants except I145T was
sufficient in potentiating receptor activity. DrFKBP52-T145I shows an approximately
50% increase in receptor activity as compared to wild type DrFKBP52 (Figure 2.7).
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A.
IDENTIFICATION OF NON-CONSERVED RESIDUES IN FK2 DOMAIN
hFKBP52
DrFKBP52
hFKBP51

150 IRRIQTRGEGYAKPNEGAIVEVALEGYYKDKLFDQRELRFEIGEGENLDLPYGLERAI 208
144 TRRIITKGEGYTKPNEGATVEVWLEGSHEDRVFDERELKFEVGDGENLGLPLGVEKAL 203
147 IRRTKRKGEGYSNPNEGATVEIHLEGRCGGRMFDCRDVAFTVGEGEDHDIPIGIDKAL 206
**
:***: .**:** **: :** .: ** *:: * :*:*:. .:* *::.*: :

hFKBP52
DrFKBP52
hFKBP51

209 QRMEKGEHSIVYLKPSYAFGSVGKEKFQIPPNAELKYELHLKSFE 253
204 QAMEQGEEALFTIKPKYGFGTAGSEKYNIPPNATLQYKIKMKAFE 246
207 EKMQREEQCILYLGPRYGFGEAGKPKFGIEPNAELIYEVTLKSFE 248
*:: *..:. : * *.** *. :: * *:*** * *:: :*:**
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Figure 2.7: FK2 Domain Comparison.
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Figure 2.7: FK2 Domain Comparison.
(A) As diagrammed at the top of the figure, the FK2 domain of DrFKBK52, hFKBP51
and FKBP52 were aligned and non-conserved residues where identified and Sitedirected mutagenesis preformed. Mutated residues are highlighted in yellow. The
activities of the FKBP constructs were assayed in yeast containing (B) wt-AR. Bars
represent the average reporter expression of a least 3 replicates (RLU/OD 600 with
SD).
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However, no functional significant was seen when co-transformed with AR-P723S.
Though this study was not successful in allowing us to identify specific domains within
the FK2 domain that significantly restored activity, it does suggest a possible interest in
the FK linker and residues in the surrounding area. Structural studies have identified
this region as palpable and flexible, allowing for various interactions with the FK1
domain (112).
2.4 DISCUSSION
The generation of cross-species chimera constructs allowed for the investigation
of the domain-specific importance of the hFKBP52 protein. Chimera constructs have
been utilized in the past, using the closely related and structurally similar hFKBP51.
Those studies demonstrated that FKBP51 and FKBP52 functionally diverged by two
residues within the FK1 proline-rich loop, and demonstrated that the proline-rich loop is
critical for FKBP52 regulation of receptor function. Utilizing a similar comparative
approach allowed our lab to take advantage of the unique characteristic found in
DrFKBP52. DrFKBP52 is similar to hFKBP52, and contains all of the critical domains
and residues known to be critical for receptor potentiation. The failure of DrFKBP52 to
modulate receptor activity like hFKBP52 is evidence that additional important residues
remain to be identified. Whether or not human FKBP52 directly interacts with the
receptor is unknown, but its association with Hsp90 is thought to bring FKBP52 into
close proximityto the receptor. However, the fact that FKBP52 displays receptor
specificity suggests that there is a direct receptor:hFKBP52 interaction, facilitated
through a specific surface contact. Identifying these residues, domains, or motifs are of
critical importance for the aim of targeting hFKBP52 as a prospective PC therapeutic
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agent.
Through this study our lab has come a step closer to establishing a functional
role for the FK2 domain in FKBP52. Chimera studies involving hFKBP52 and
DrFKBP52 strongly imply that the FK2-domain is an important regulator of FKBP52
activity. This study also suggests that the FK2 domain may be more important in
augmenting AR:FKBP52 activity than the critical proline-rich loop. This is not surprising
as recent studies by (112) identified a dynamic and fluid interaction between the FK1
and FK2 domain, facilitated by the FK1-linker region. Rather than simply being
redundant and non-functional, the FK2 domain could very well be a key player in
receptor activity as indicated by Chimera ZHZ-150_253.
In summary, we have revealed a unique role for the FKBP52 FK2 domain in
potentiating AR and GR activity. The FK1 domain of hFKBP52, in exchange, did not
potentiate receptor activity. This paradox is unexplainable, as past studies have shown
that the FK1 domain is critical for activity. There could be a structural restriction and
consequences when exchanging domains that are not identifiable by biochemical
studies and would need further probing to determine. Be this as it may, the sole
contributor to Chimera ZHZ-150_253 activity is the hFKBP52 FK2 domain, which places
significant weight on its importance in hFKBP52’s activity in regulation of steroid
hormone receptors. The FK2 domain has not been evaluated as a possible target, but
might be a plausible option now that we know it has an important role in hFKBP52
activity.
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CHAPTER 3: FUNCTIONAL RANDOM MUTAGENESIS OF hFKBP52 IN
COMPARISON TO DANIO RERIO FKBP52
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3.1 RATIONALE
As stated previously in section 2.1, the studies using FKBP51 identified residues
important for hFKBP52 activity. However, critical residues remain to be identified. We
hypothesize that other residues exist within the hFKBP52 FK1 and/or FK2 domains that
are required for full activity. Random mutagenesis was utilized with great success to
identify the divergent differences in FKBP51 and FKBP52, thus we will utilizes this same
approach utilizing differences between DrFBKP52 and hFKBP52.
3.2 EXPERIMENTAL DESIGN
3.2.1 Yeast Strains and Β-Galactosidase Reporter Assays
The β-galactosidase reporter assays that were used as a quantitative measure of
receptor activity were described previously (25). For hormone-responsive reporter
assays, the indicated strains were co-transformed with three to four plasmids: a
hormone-inducible β-galactosidase reporter plasmid (pUCΔss-26X [reporter]), a plasmid
constitutively expressing the indicated steroid hormone receptor from a glyceraldehyde
phosphate dehydrogenase (GPD) promoter, and high-copy number plasmids
expressing yeast parent vector, human FKBP52, Danio rerio FKBP52, and/or sitedirected mutants where indicated. Human AR and the mutant AR-P723S were cloned,
respectively, into p424GPD and p424TEF. All hormones were obtained from Sigma (St.
Louis, MO) and were stored as 50 mM stock solutions in ethanol. Hormone dilutions
were setup so that the ethanol vehicle never exceeded 1% in the yeast cultures. The
hormone concentrations were optimized in order to maximize the difference between
cells carrying an empty vector versus cells carrying an human FKBP52 expression
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vector by performing dose-response curves. Hormone-induced reporter activity was
measured from yeast extracts as described previously with a single two-hour time point
measurement. To determine the rate of reporter expression, galactosidase induction
curves were first generated by plotting relative light units (RLU) against the A600 of the
culture sample (OD600/ β- galactosidase RLU). The normalized levels of reporter
expression are normalized to 100% expression and reported in graphical form using
GraphPad. All assays were performed at least in triplicate and the data shown are
representative of at least three independent experiments that produced consistent
results.
3.2.2 Site-Directed Mutant Plasmids
Mutations were introduced by site-directed mutagenesis (QuikChange II XL;
Stratagene, San Diego, CA) into the wild-type human FKBP52 or Danio rerio FKBP52
gene cloned into p423GPD. Potentiation by these mutant FKBPs was measured in
strain W303a transformed with the reporter plasmid (pUCΔss-26X) and AR or AR
P723S expression plasmid. Dihydrotestosterone (DHT) (3 nM or 10 nM stock) was used
in the wild-type AR and AR-P723S assays.
3.2.3 Selection for FKBP51 Potentiation Mutants and Analysis
The mutant FKBP51 library was made using error-prone PCR (GeneMorphII;
Stratagene, CA) using the manufacturer’s recommended conditions for Low-frequency
mutagenesis (50-100ng target DNA per reaction). The template used was p425GPDDrFKBP52, and the primer binding sites were approximately 100 bases outside of the
gene borders. The PCR product (400 ng, purified by agarose gel electro- phoresis) and
p424GPD vector (100 ng, linearized with EcoRI and SalI) were cotransformed into the
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selection strain YNK435 (MATa ura3-52 lys2-801 ade2- 101 trp1-Δ63 his3-Δ200 leu2Δ1 pdr5::GT3Z his3::GT3H) containing the plasmid p425TEF-AR-P723S. DrFKBP52
potentiation mutants were selected on plates containing synthetic complete medium
lacking tryptophan, leucine, and histidine (SC-WLH) supplemented with 10 nM DHT and
10 mM 3-amino-1,2,4-triazole (3AT). The concentrations of each were adjusted to
maximize the growth differential between YNK435 strains expressing either hFKBP52 or
DrFKBP52. The colonies that grow comparable to hFKBP52 were selected. The mutant
phenotype (potentiation of hormone signaling) was confirmed by assaying hormonedependent expression of the β-galactosidase reporter in the selection strain. Isolates
that showed increases in both hormone-dependent growth and β-galactosidase
expression were confirmed by transferring the mutated DrFKBP52 gene into a clean
genetic background. This was done by extracting the mutated DrFKBP52 from yeast
lysates. The extracted mutant was transformed into strain W303a expressing AR-P723S
and

containing

a

plasmid-encoded

hormone-responsive

β-galactosidase

gene

(pUCΔss-26X). Transformants were assayed for potentiation of hormone signaling as
described above. Those mutated DrFKBP52 genes that retained the potentiation
properties in this clean genetic background were then sequenced, and interesting
mutations were put in individually and in combination into the DrFKBP52 gene by sitedirected mutagenesis.
3.2.4 Yeast Plasmid Extraction
Cells are selected and cultured overnight in selective media at 30°C. Cells were
then lysed according to a standard Western blot protocol. Cell lysates were then
minipreped (Pure Yield Plasmid miniprep system, Promega Madison, WI). Samples
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were eluted off of the column with 50 µl of cold nucleus free water. Samples were than
transformed into DH5α and plated on Luria Bertani media with Ampicillin.
3.2.5 Hormone-Induced Gene Expression In Mouse Cells
For assays, immortalized mouse embryonic fibroblasts (MEF) derived from
FKBP52 knockout mice (Tranguch, S., et al 2005), were cultured in 5% CO2 in HyClone
Minimal Essential Media/Eagles Essential Salt Solution with 2 mM L-glutamine (Thermal
Scientific, Logan, UT) supplemented with 10% Charcoal/Dextran Treated Fetal Bovine
Serum (FBS) (HyClone, Logan, UT) 24 hours prior to the transfection. Cells were
cultured in 6-well plates until they were 80% confluent. They were transfected in
triplicates using lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. Transfections were performed for 5 hours at a DNA to
lipofectamine ratio of 1:3 in MEM-EBSS lacking FBS. The transfection cocktail was
mixed as follows: 50 ng of the pCMVβ β-galactosidase normalizing reporter plasmid
(Clonetech, Mountain view, CA), 400 ng of pT81 (American Type Culture Collection,
Manassas, VA) plasmid expressing firefly luciferase reporter driven by the androgendependent Probasin promoter. 800 ng of the pCI-Neo plasmid (Promega, Madison,WI)
expressing human AR, and 800 ng of the pCI-Neo plasmid expressing hFKBP52,
DrFKBP52, and/or DrFKBP52 mutants, with 800 ng of pCI-Neo plasmid containing
normalizing vector.
Twenty-four to thirty hours after transfection, medium was replaced with medium
containing 10 pM DHT (or a range of doses, as appropriate). After approximately
fourteen-sixteen hours of incubation with hormone, cells in each well were lysed using
100 µL mammalian protein extraction reagent (M-PER) (Pierce, Rockford, IL)
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supplemented with Complete ethylenediaminetetraacetic acid (EDTA)-free Mini
Protease Inhibitor (Roche, Manheim, Germany) and spun at 15,000 rpms in a 4*C
microcentrifuge to remove impurities. Luciferase expression was quantified by mixing 40
µL cell lysate with 100 µL of luciferase assay reagent (Promega, Madison, WI) in a
single well for each sample on a 96-well plate. β-galactosidase expression was
quantified by adding 20 µL cell lysate with 100 µL of Gal Screen Reagent (Tropix,
Bedford, MA). The 96-well plates were incubated at room temperature, followed by
quantification of luminescence by a microplate luminometer (Luminoskan Ascent,
Thermo Labsystems). Luminescence was measured in Relative Light Units (RLU). The
transfection-efficiency normalized levels of reporter expression (luciferase RLU/ βgalactosidase RLU) were reported in graphical form using Graphpad Prism software
and were all normalized to 100% expression.
The data shown in the composite promoter graph represent five independent
experiments plus/minus standard deviation of at least two separate samples, and
figures are composite graphs representing data from at least three independent
experiments.
3.2.6 Western Blot
Yeast cells growing overnight were diluted to an OD600 of approximately 0.2 and
grown until the OD600 reached 0.8. For Western blot to detect receptors, which tend to
precipitate in yeast lysates, yeast cells were pelleted, resuspended in extract buffer [20
mM Tris (pH 7.5), 100 mM NaCl, 5% glycerol supplemented with protease inhibitors]
and vortexed vigorously in the presence of glass beads. Lysates were then clarified at
15,000 rpm for 20 min at 40C. For mammalian cell lysis, cells were washed with 1X PBS
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and lysed with mammalian protein extraction reagent (M-PER; Pierce, Rockford, IL)
supplemented with protease inhibitors (Complete mini EDTA-free; Roche, Indianapolis,
IN). Protein concentrations for both yeast and mammalian extracts were determined by
Coomassie Plus Protein Assay (Pierce, Rockford, IL). Typically 40 µg of total cellular
protein was separated on a 10-20% Criterion gels (Bio-Rad, Hercules, CA) and
transferred to polyvinylidene difluoride membranes. The following antibodies were used:
rabbit α-human SGTα (Protein Tech Group, Chicago, IL), mouse monoclonal α-FKBP52
(HI52B, HI52C, HI52D), rabbit α-human AR (Santa Cruz Biotechnology, Santa Cruz, CA
), and rabbit α-human GR (Santa Cruz Biotechnology, Santa Cruz, CA). Antibodies
detecting yeast ribosomal protein L3 (a gift from Jonathan Warner, Albert Einstein
College of Medicine) and Glyceraldehyde-3-phosphate dehydrogenase (6C5; Biodesign
International, Saco, MN) were used as loading controls. The secondary antibodies were
alkaline phosphatase-conjugated goat anti-mouse or anti-rabbit antibodies and bands
were visualized with Immune-Star AP substrate (Bio-Rad, Hercules, CA) and exposed
to X-ray film.
3.3 RESULTS
3.3.1 Designing and Optimizing the Gain-of-Function Random Mutagenesis
Screening Strain
As stated previously comparative analysis is a very powerful tool for the
identification of relevant functional domains and/or residues.

Riggs et al. utilized

random mutagenesis to identify the proline-rich loop region that overhangs the catalytic
pocket on hFKBP52 as being critical for FKBP52 function (6). This same proline-rich
loop is present in DrFKBP52, so we used this method to identify additional residues
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necessary for hFKBP52 activity. Our thorough assessment of DrFKBP52 led us to the
conclusion that it would be an excellent model protein for gain-of-function comparative
analysis with hFKBP52 (Section 2.3.1).
Our initial experimental model for the random mutagenesis was based on the
protocol used by Riggs et. al. (6). However, after a year of false positives, failed
experiments, and inconsistent data, it was determined that we had to completely reoptimize this protocol for our needs. We re-created the screening strain, as it was a
major contributor to inconsistent data. We also optimized hormone and 3AT
concentration, which distinguishes hormone-dependent growth efficiency. These
optimizations were essential in making this experiment model a success and are
discussed further.
Our first step was to regenerate a random mutagenesis screening yeast strain
containing an androgen receptor-mediated HIS3-selectable reporter (Figure 3.3). Thus,
in the presence of hFKBP52-potentiated receptor activity the strain could grow robustly
on histidine-lacking medium. However, in the presence of DrFKBP52, which does not
potentiate receptor activity, the strain would grow very poorly on histidine-lacking
medium. Only in the presence of of the gain-of-function DrFKBP52 mutants could the
strain grow robustly on histidine-lacking medium in the absence of hFKBP52.

The

selection strain YNK435 (MATa ura3-52 lys2-801 ade2- 101 trp1-Δ63 his3-Δ200 leu2Δ1 pdr5::GT3Z his3::GT3H) was transformed with AR-P723S, hFKBP52, DrFKBP52, or
vector. hFKBP52 was used as a positive growth control, and vector as the negative
growth control. We then used this newly transformed strain to identify the optimal DHT
concentration that allowed for growth of the hFKBP52 strain, but minimal to no growth of
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vector and DrFKBP52 strains. We added 1 nM, 5 nM, 10 nM and 20 nM DHT to
selective media plates lacking histidine and titrated cell density for each sample at 100,
500, 1000, 5000, 10000 cells/spot (Figure 3.1). Spot tests indicated that 5 nM or 10 nM
was sufficient to distinguish hormone-dependent growth between the hFKBP52 and
DrFKBP52 strains. Because robust growth of hFKBP52 cells were seen on selective
media plates containing 10 nM DHT, this dose was chosen.
In an effort to control for leaky HIS3 gene expression, and to reduce vector and
DrFKBP52 background, we optimized 3-amino-1,2,4-triazole (3-AT) concentrations. The
reagent 3-AT was used because it is a competitive inhibitor of the HIS3 gene product,
imidazoleglycerol-phosphate dehydratase. Imidazoleglycerol-phosphate dehydratase is
an enzyme catalyzing the sixth step of histidine production. Spot tests were done using
5, 10, 15, and 20 mM 3-AT at 10 nM DHT on selective media plates lacking histidine.
Each strain was spotted at 100, 500, 1000, 5000, and 10000 cells/spot (Figure 3.2). We
determined that 10 mM 3-AT is sufficient to suppress vector and DrFKBP52 background
growth, yet would not be toxic to yeast.
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Figure 3.1: Dihydrotestosterone Optimization for Random Mutant Screening.
Various DHT concentrations were selected and hormone dependent cell growth was
assessed. Cells were grown on SC-LW Plates containing hormone and 5 mM 3-AT.
Spot test were performed at 10,000, 5,000, 1,000, 500, and 100 cells/spot.
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Figure 3.2: 3-AT Optimization for Random Mutant ScreeningVarious
3-AT concentrations were assessed for the ability to suppress leaky expression of the
HIS3 reporter. Cells were grown on SC-LW Plates+10nM DHT+3AT. Spot test were
performed at 10,000, 5,000, 1,000, 500, and 100 cells/spot.
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Our next step was to remove the DrFKBP52 expression plasmid from our
selection strain, through replica plating, in order to start with a DrFKBP52 negative
background in which to put the DrFKBP52 random mutants. In this method, a plasmidbearing yeast strain is grown non-selectively twice overnight (to allow loss of the
plasmid). Cells are than plated at a very low density on selective media plates. Colonies
lacking the plasmid are identified by replica plating onto selective media plates lacking
the specific nutritional supplement encoded by the marker gene on the plasmid of
interest. If the plasmid is lost those colonies would not grow on media lacking the
selective nutritional supplement. We were able to identify five isolates from the replica
plating. We selected three of the isolates to use for a functional yeast assay to
determine which strains would be used for random mutagenesis. Vector, hFKBP52, and
DrFKBP52 expression plasmids were co-transformed into each strain and incubated for
4 days at 30°C. Three isolates were selected from each plate and assayed for functional
competency. Human FKBP52 and vector isolates were kept as hormone-dependent
growth controls for random mutagenesis screening.
3.3.2 Genetic Screen for Danio rerio FKBP52 Random Mutants that Up-Regulate
AR-P723S Activity
A plausible explanation for the functional diversity between hFKBP52 and
DrFKBP52 is that DrFKBP52 likely lacks critical residues necessary for productive
interaction with the steroid hormone receptors. In this study such residues were
selected for, through yeast genetics, by evaluating gain-of-function mutations in
DrFKBP52 that allow it to potentiate the hormone signaling pathway in a manner similar
to that of hFKBP52. The yeast selection strain described in section 3.3.1 was used for
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these studies. This strain is unique in that its genome has been manipulated to express
HRE:HIS3 and an HRE:LacZ reporter gene. The HIS3 gene is attached to a weak
promoter having an adjacent upstream hormone response element (Fig. 3.3). A HIS3
inhibitor, 3-AT, was added to the growth medium, to control for leaky expression of the
HIS3 construct in the absence of hormone. This strain stably expresses AR and
medium-lacking histidine was dependent upon the ligand dihydrotestosterone (DHT).
This allowed for us to have selectivity bases on growth, which was equivalent to
hormone binding and receptor activity. Figure 3.3 shows robust growth in yeast cells
expressing hFKBP52, in medium supplemented with DHT. While little or no growth was
detected in yeast expressing DrFKBP52 or Vector. This strain also expressed AR
P723S, a point mutant, which is hyperdependent on FKBP52 for hormone-induced
activity.
To generate DrFKBP52 gain-of-function mutants that support DHT-dependent
yeast growth, we utilized the random mutagenesis method previously used in the
FKBP51 study (6). Random mutagenesis was optimized to produce three to five
mutations per PCR product. PCR products were gel purified and co-transformed with
linearized vector into yeast cells. Transformed product was plated on the selective
growth medium and incubated until distinct colonies appeared, about 1 week. As a
control, vector, DrFKBP52, and hFKBP52 were also grown on separate plates, to
adequately assess DHT-dependent yeast growth. In addition, the hormone-responsive
β-galactosidase reporter gene was independently utilized to confirm and quantify DHTinduced β-galactosidase activity in liquid culture.
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Figure 3.3: Scheme for the Identification of Danio rerio FKBP52 Random Mutants that
Up-Regulate the Phenotype of the AR-P723S.
(A). Libraries of random Danio rerio FKBP52 mutants were independently generated by
error- prone PCR using primers binding upstream in the vector yeast GAPDH promoter
(PGPD) or downstream in the transcriptional terminator (Term). Mutant libraries were
co-transformed with a linearized vector such that homologous recombination between
the common promoter and terminator regions on these fragments (about 100
nucleotides each) reconstitutes a TRP1- marked Danio rerio FKBP52 expression
plasmid. The parental strain harbors a LEU2-marked AR- P723S expression plasmid
and integrated HIS3 and lacZ reporter genes driven by hormone- responsive promoter
element (HRE). Transformants were plated on selective growth medium plates
supplemented with 10mM 3-amino-1, 2, 4-triazole and 10nM DHT. To confirm that
growth was dependent on mutant DrFKBP52 a liquid assay was performed using parent
strain expressing AR-P723S and laZ reporter plasmid. Identified up-mutants, exhibiting
the gain-of- function phenotype, were extracted from yeast and co-transformed into
secondary strains expressing WT-AR and laZ reporter plasmid. The Danio rerio
FKBP52 mutant genes were sequenced to identify relevant mutations. (B) Yeast strains
containing a hormone-inducible HIS3 gene and expressing AR plus either Vector,
hFKBP52 or/and Danio rerio FKBP52 were grown on selection medium containing a
growth-limiting concentration of 10nM DHT, as described in Materials and Methods.
Yeast grows well only in the presence of FKBP52, which potentiates AR activity.
To ensure that DrFKBP52 mutant potentiation was not yeast strain-dependent, the
mutant DrFKBP52 gene was transferred into a clean background strain transformed
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with a different hormone-inducible β-galactosidase reporter and wild type AR or ARP723S. If the mutants maintained their ability to augment the receptor activity, the
mutant gene was sequenced.

77

Mutants were isolated from numerous independent error-prone PCR reactions,
with the expectation that key mutations would repeatedly arise. A total of 34 gain-offunction mutants were isolated from twelve independent libraries; of these, 12 had
mutations in FK1: F49S and A116V/T, and 9 were located in the FK2 domain the
T157R/A, and S172Y (Figure 3.4). Each was isolated multiple times from independent
libraries. The DrFKBP52 A111 is analogous to hFKBP52 A116 and, although the
residues are the same in both proteins, previous studies comparing FKBP51 suggested
that changing this alanine to a valine in FKBP51 also conferred gain-of-function to
FKBP51 (6) Random mutant S172Y was also previously evaluated for potentiation
activity, but no effects were seen (Figure 2.7), However, residues F49, T157 do show
functional sequence divergence and maybe important for receptor activity.
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Figure 3.4: Danio rerio FKBP52 Potentiating Mutants Isolated in the Selection
Strain.
The top map represents the domain arrangement of DrFKBP52 in a linear manner with
amino acid numbering at the domain boundaries. Isolated mutants are aligned below.
Each mutant is identified by the PCR round from which it was isolated (E to R) and an
isolate number. Repeatedly identified mutations of particular interest are shown in bold
and underlined.
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3.3.3 Characterization of DrFKBP52 Mutants
To confirm the individual role of each identified mutant, site-directed mutagenesis
was utilized to generate the corresponding point mutant in wild type DrFKBP52. Mutants
were analyzed in yeast expressing either wild type AR or AR-P723S. The residues at
position 111 and 157 are critical for DrFKBP52 potentiation as the A111V and T157R
DrFKBP52 mutants were able to potentiate AR signaling approximately 3- to 5-fold that
of wild type DrFKBP52 when co-expressed with wild type AR (Figure 3.5A). However,
AR-P723S showed only a 2-fold enhancement. Remarkably, when A111V and T157R
are combined DrFKBP52 potentiated signaling comparable to hFKBP52 alone, in both
wild type AR and AR-P723S strains (Figure 3.5A and B). A similar analysis was
performed in 52KO MEF cells, where similar results were obtained (Figure 3.5C). The
mutant F49S was co-expressed with wild type AR, but we did not observe any
significant regulation of receptor function as compared to wild type DrFKBP52. Western
blot analysis indicated equal FKBP expression levels and stable expression levels of
receptor proteins.

80

to
D r
r5
2
H
52
A1
11
T1 V
5
T1 7A
57
R

Ve
c

% Reporter Expression

% Reporter Expression
125

0

Ve
ct
or
D
r5
2
H
52
A1
11
V
T1
A1
5
11
V+ 7R
T1
57
R

Ve
ct
o
D r
r5
2
H
52
S4
T 1 9F
5
A1 7A
11
A1
11 T1 V
A V 57
11 +T R
1V 1
+ T 57
15 A
7R
Wt-AR

100

75

50

25

Fold Induction (luc./ -gal)

A.
C.

0

81

25 52KO MEF

20

15

10
5

0

AR

SD Mutant

L3

B.

125 AR- P723S

100

75

50

25

7A 7R
5
5
T1 T1
+
+
V V
11 11
1
A A1

Figure 3.5: Functional Analysis of Amino Acids at Positions 49, 111, and 157.

Figure 3.5: Functional Analysis of Amino Acids at Positions 49, 111, and 157.
(A) Hormone-dependent reporter gene activity was measured in yeast strains
expressing wild- type AR (3nM DHT) and AR-P723S (10nM DHT) plus the indicated
FKBP. The single mutants (right) and double mutants (left) were assayed for activity.
Relevant single and double mutants were assayed in FKBP52 hyper-dependent AR
mutant P723S (bottom). Protein expression levels were monitored by Western
immunostaining for the introduced AR- P723S, FKBP and the endogenous ribosomal
subunit L3. (B) FKBP activities were similarly determined in transfected 52KO MEF cells
expressing wild-type AR and a hormone-dependent luciferase reporter. Protein
expression levels were monitored by Western immunostaining for the introduced FKBP,
AR, and endogenous GAPDH.
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3.3.4 Characterization of Chimera ZHZ-150_253 in Combination With A111V
These results indicate that A111 in DrFKBP52 has a role in the ability to
potentiate AR signaling. We used Chimera ZHZ-150_253 to map protein regions that
influence potentiation and further evaluate the role of the FK2 domain. In previous
studies, the FK1 domain appears to be the sole difference with respect to potentiation of
AR. Chimera ZHZ-150_253 contains the DrFKBP52 FK1 and TRP domains and the
hFKBP52 FK2 domain. When Chimera ZHZ-150_253 is combined with A111V it results
in levels of potentiation equivalent to that observed with hFKBP52 in both wild type AR
and AR-P723S (Figure 3.6). Separately, Chimera ZHZ-150_253 and A111V had
intermediate levels of potentiation. Results suggest full activity differences between
hFKBP52 and DrFKBP52 are to be attributed to both the proline-rich loop within FK1
and the FK2 domain.
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Figure 3.6: Functional Analysis of Chimera ZHZ-150_253 with A111V Mutation.
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Figure 3.6: Functional Analysis of Chimera ZHZ-150_253 with A111V Mutation.
(A) Hormone-dependent reporter gene activity was measured in yeast strains
expressing wild- type AR at 3nM DHT and the indicated Chimera and Site-directed
mutant FKBP. (B) FKBPs activities were similarly determined in AR-P723S at 10nM
DHT. Protein expression levels were monitored by Western immunostaining for the
introduced wt-AR, AR- P723S, FKBPs and the endogenous ribosomal subunit L3.
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3.3.5 Mutation of DrFKBP52 A111 AND FKBP52 A116
Although this analogous residue has been identified in a previous study (6), the
significance of this residue was not fully understood. This residue is positioned on the
periphery of the proline-rich loop region. Here we have attempted to uncover its
importance in hFKBP52 activity. We have done this through evaluating the effects of
different amino acids residues at this position in both FKBPs. These mutations were
introduced by site-directed mutagenesis and co-transformed into yeast expressing wild
type AR or AR-P723S. It was observed that hydrophobic residues valine, lysine, and
tyrosine have the greatest ability to enhance receptor function with valine having
maximal potentiation, in both FKBPs (Figure 3.7). Negativly charged amino acids,
glutamic acid and aspartic acid, drastically decrease activity to approximately 50% that
of hFKBP52 and no effects are seen in DrFKBP52. A moderate decrease is also seen
with Arginine for both FKBPs in the wild type AR strain (Figure 3.7A). Although ARP723S drastically shows the divergence in activity between the amino acids, the trend is
consistent. It should be noted that we observe a 40% increase in potentiation with the
hFKBP52-A116V mutation in the regulation of AR-P723S (Figure 3.7C). The identical
trend in amino acid modulation between hFKBP52 and DrFKBP52 strengthen the
evidence that this residue has importance in the proline-rich loop region and interaction
with the receptor, specifically the BF3 surface.
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Figure 3.7: Functional Modulation of FKBP A111 and A116 Mutations.

Figure 3.7: Functional Modulation of FKBP A111 and A116 mutation
(A). AR signaling and FKBP expression was assayed in yeast, DrFKBP52: A111V and
hFKBP52: A116V or (C) AR:P723S, only hFKBP52: A116V. Hormone-dependent
reporter gene activity was measured in yeast strains expressing wild-type AR (3nM
DHT) and Dr52 FKBP Site- directed mutants (B) Human FKBP52 FKBP Site-directed.
(C) Relevant hFKBP52 single mutants were assayed in hFKBP52 and hyper-dependent
AR:P723S (10nM DHT). Protein expression levels were monitored by Western
immunostaining for the introduced AR- P723S, FKBP and the endogenous ribosomal
subunit L3.
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3.3.6 Mapping Other Relevant Residues in the FK2 Domain
Our results indicate a role for the FKBP52 FK2 domain in the potentiation of
steroid hormone receptor signaling, yet specific residues are unknown. DrFKBP52T157R has the capacity to enhance AR function, so we propose that hFKBP52 activity
could be conveyed by the arginine-rich region near the FK linker (Figure 3.8A). It should
be noted that converse mutation in hFKBP52 had no effect on receptor activity.
However, this arginine-rich region is located 15 amino acids away from this residue.
Crystal structure shows that these residues are on the surface of the protein. The
hFKBP52 and DrFKBP52 crystal structures were superimposed to determine orientation
of residues (Figure 3.8B). We used site-directed mutagenesis to generate hFKBP52R152A, -R153A, and -R157A expressions plasmids, which were then co-expressed with
wild type AR and functional yeast assays were performed to assessed activity.
Functional yeast assays determined that all three mutants significantly abrogated
hFKBP52 ability to potentiate wt-AR activity (Figure 3.8C). These arginine residues are
positively charged, allowing the side chains to participate in protein-protein interactions
and ionic bonding, which could be important for interaction with the FK1 domain or
receptor.
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Figure 3.8: Functional Analysis of Arginine Motif
(A) hFKBP52 and DrFKBP52 FK1-FK2 domains were superimposed to determine
placement of Arginine in relation to the orientation of the proline-rich loop. hFKBP52
(green and red) and DrFKBP52 (yellow and purple). (B) ClustalW2 alignment shows
residue conservation. (C) Hormone-dependent reporter gene activity was measured in
yeast strains expressing wild-type AR at 3nM DHT and the indicated Site-directed
mutant FKBP. Protein expression levels were monitored by Western immunostaining for
the introduced wt-AR, AR- P723S, FKBPs and the endogenous ribosomal subunit L3.
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3.4 DISCUSSION
Human FKBP52 is a known positive regulator of hormone-dependent
transcriptional activity of steroid hormone receptors. Its physiological relevance has
been established in male and female mice FKBP52 knockout results in reproductive
abnormalities. The mechanistic basis for receptor potentiation is still poorly understood,
however, recent studies implicate its presence at the transcription level (107). It is
known that FKBP52 assembles with receptor complexes through association with
Hsp90, and exerts its effect on the receptor activity. In particular the N-terminal, FK1
PPIase domain of hFKBP52 has been recognized as important for activity, but not
sufficient for full activity. The FK1 domain importance is further established by the lack
of receptor potentiation in the presence of the FK506 ligand, which binds the PPIase
pocket (25). Further evidence was obtained in a previous study comparing the highly
similar FKBP51 protein. Gain-of-function random mutagenesis determined that the
double A116V and L119P mutation enable the nonfunctional FKBP51 to potentiate
receptor activity similar to that of FKBP52 . Converse mutations identified that the
P119L mutation reduced receptor function by 40%, leading to the conclusion that the
proline-rich loop region is critical for receptor potentiation. However, the significance of
the A116V mutation was still unclear and the FK2 domain unrecognized (6). However,
previous findings implicate the FK2 domain as having a role in potentiation (25, 109,
113).
Despite the presence of the proline-rich loop, CKII site, Hsp90 binding motif, and
many other similarities to hFKBP52, DrFKBP52 does not potentiate receptor activity.
DrFKBP52 was randomly mutated, and a yeast genetic screen created to isolate
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DrFKBP52 mutants that gain potentiation activity (Figure 3.3). The gain-of-function
mutants that were repeatedly identified were A111V (9 independent identifications) and
T157R (7 independent identifications) (Figure 3.4). Separately, these mutants had
sufficient activity to increase potentiation of wild type AR three to five-fold, as compared
to DrFKBP52 (Figure 3.5). Remarkably, the DrFKBP52-A111V/T157R double mutant
completely restored activity similar to that of hFKBP52 in yeast and mammalian cells
(Figure 3.5). DrFKBP52-F49S and -S172Y did not confer potentiation in any of the yeast
strains. It should be noted that the T157A mutant was able to confer activity separately,
however, the double mutant A111V/T157A did not function like hFKBP52 or its
counterpart DrFKBP52-A111V/T157R; implying a specific possible interaction between
the FK1 and FK2 domains or specific, but separate contact with the receptor. Though
converse mutation in hFKBP52 did not affect activity, the reoccurrence of residue A116
in this study implicates it again as an important residue. Since DrFKBP52 and hFKBP52
both naturally contain alanine at positions 111 and 116 respectively, we tested whether
modulating these residues would have potentiation activity exceeding that of wild-type
hFKBP52 (Figure 3.7B and C). The hydrophobic residues at this position in DrFKBP52
produced only a small increase in potentiation of wild type AR, while the positive and
negative

residues

significantly

reduced

potentiation

ability.

This

was

further

corroborated with AR-P723S where a dramatic increase in potentiation was seen with
the hydrophobic residues and a drastic reduction of potentiation was seen with positive
and negative residues (Figure 3.7C). The same trend was seen in DrFKBP52 (Figure
3.7A). These results highlight the importance of the residue, however, its significance
was still unclear.
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We have also indicated a plausible important region located upstream of FK1
linker region.

We presume that the FK2 domain role has been firmly established

through chimera data, but its relevance is still unclear. The DrFKBP52-T157R mutant is
very efficient in enhancing receptor function, yet the converse mutation in hFKBP52 had
no significant effects (Data not shown). Interestingly, this mutation is located downstream of a highly conserved stretch of residues (IRRIQTR), a positively charged and
hydrophobic region. Like the proline-rich loop region it is highly conserved between
DrFKBP52, FKBP52 and FKBP51 species. We have determined that changing any of
these arginines to alanine in hFKBP52 abrogates potentiation by up to 60% (Figure
3.8). Because this region is highly conserved it could be necessary for conformational
integrity like position A116 and not strictly a sequence difference. Though we have not
confirmed a specific residue in the FK2 domain that is important for hFKBP52’s
potentiation, we postulate that it may be near the FK1 linker region and may facilitate a
specific interaction with the FK1 loop region.

This is suggested by the DrFKBP52

double mutant can potentiate the receptor like hFKBP52. This is exciting because we
have established another possible target for inhibitor design.
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CHAPTER 4: FKBP HOMOLOGY MODELING
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4.1 RATIONALE
Our observation in Aim 3 revealed a positive regulatory role for position
DrFKBP52-A111 and hFKBP52-A116. The analogous residue was also identified as
having a positive affect in FKBP51 regulation of steroid hormone receptor signaling.
The reoccurrence of this mutation indicates that it could be an important residue in
FKBP52 activity. Because biochemical studies alone do not convey the structural
significance as it relates to function we have utilized structural studies to further elute
the importance of this residue. To resolve the structural changes in DrFKBP52-A111V
that contribute to the gain in activity we used homology modeling.
Homology modeling, also known as comparative modeling, is a method in which
the atomic-resolution model of a target, “unknown” protein is formed using an
experimentally resolved three-dimensional structure of a homologous protein “template”.
Many of the experimental method use to resolve 3D structure such as X-ray
crystallography and protein NMR are complex and time-consuming. Homology modeling
provides useful structural models for generating a hypotheses about a protein's function
and directing further experimentation. It is also useful in reaching qualitative conclusions
about the biochemistry of the target sequence, especially in understanding why certain
residues are conserved (116). Though evolutionarily related proteins change in amino
acid sequence, the overall three-dimensional protein structure is evolutionarily more
conserved than would be expected on the basis of sequence conservation. For this fact
we used hFKBP52 and hFKBP51 for homology modeling with DrFKBP52 and
DrFKBP52-A111V.
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We hypothesize that a comparative structural analysis of hFKBP52, hFKBP51,
DrFKBP52 and DrFKBP52-A111V will reveal key structural elements that contribute to
FKBP52 activity. Because this point mutant is near the proline-rich loop, it could also be
helpful in determining the surface area important for protein-protein interaction.
4.2 MATERIAL AND METHODS
4.2.1 Template Recognition and Initial Alignment
We used NCBI:Pubmed for template and target proteins selection and extraction
(http://www.ncbi.nlm.nih.gov/pubmed). Basic Local Alignment Search Tool (BLAST) was
used to determine template sequence homology by specific parameters. The quality of
the homology model is dependent on the quality of the sequence alignment and
template structure. The approach can be complicated by the presence of alignment
gaps that indicate a structural region present in the target but not in the template.
Model quality also declines with decreasing sequence identity. Sequence alignment tool
is necessary to adequately evaluate homology-modeling compatibility for template and
target.
4.2.2 Alignment Correlation
To create the model we need a sequence alignment file between our target and
the selected template sequences of FKBP51, DrFKBP52, FKBP52 and DrFKBP52A111V. For this aim, we will use another online server, the multiple sequence alignment
ClustalW2. The sequence for the selected template can be obtained directly from the
BLAST webpage or from the PDB website (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
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4.2.3 I-TASSER Homology Modeling
DrFKBP52 and DrFKBP52-A111V amino acid sequence was submit to ITASSER for homology modeling (http://zhanglab.ccmb.med.umich.edu/I-TASSER/).
Results were then individually assessed using molecular modeling software,
MacPyMOL.
4.3 RESULTS
4.3.1 FKBP Sequence Alignments
BLAST and ClustalW2 sequence alignment indicates that both FKBP51 (Figure
4.2 and 4.3) and FKBP52 (Figure 2.1 and 4.1) are suitable templates to render high
quality homology modeling. In both template alignment models the gaps are 0%, the
absence of sequence gaps is important for accurate predictions of the structural loop.
The Expect-value (E-value) is less than 1, this is the number that gives the average for
false positives, which is a measure of alignment reliability. The E-value of FKBP51 and
FKBP52 alignment with DrFKBP52 E-values is close to 0 making them reliable
matches. Their sequence identity is also above 50%, which make each template optimal
for comparative modeling (Figure 4.1 and 4.2).
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PEPTIDYL-PROLYL CIS-TRANS ISOMERASE FKBP4 [HOMO SAPIENS]
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Figure 4.1: FKBP52 and DrFKBP52 BLAST Sequence Alignment
Sequence was aligned using BLAST alignment software. Accession numbers:
NP_002005 (FKBP52) and NP_958877 (DrFKBP52).
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Figure 4.2: FKBP51 and DrFKBP52 BLAST Sequence Alignment
Sequence was aligned using BLAST alignment software. Accession numbers:
NP_001139247 (FKBP51) and NP_958877 (DrFKBP52).
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FKBP51
DrFKBP52

MTTDEGAKNNEESPTATVAEQGEDITSKKDRGVLKIVKRVGNGEETPMIGDKVYVHYKGK 60
MTAEEVVNEG-----CSIPIEGEDITPKKDGGVLKLVKKEGTGTELPMIGDKVFVHYVGT 55
**::* .::.
.::. :*****.*** ****:**: *.* * *******:*** *.

FKBP51
DrFKBP52

LSNGKKFDSSHDRNEPFVFSLGKGQVIKAWDIGVATMKKGEICHLLCKPEYAYGSAGSLP 120
LLDGSQFDSSRDRGEKFSFELGKGQVIKAWDIGVATMKIGEICQLTCKPEYAYGAAGSPP 115
* :*.:****:**.* * *.****************** ****:* ********:*** *

FKBP51
DrFKBP52

KIPSNATLFFEIELLDFKGEDLFED--GGIIRRTKRKGEGYSNPNEGATVEIHLEGRCGG 178
KIPPNATLLFQVELFDFRGEDITDDEDGGITRRIITKGEGYTKPNEGATVEVWLEGSHED 175
***.****:*::**:**:***: :* *** **
*****::********: ***
.

FKBP51
DrFKBP52

RMFDCRDVAFTVGEGEDHDIPIGIDKALEKMQREEQCILYLGPRYGFGEAGKPKFGIEPN 238
RVFDERELKFEVGDGENLGLPLGVEKALQAMEQGEEALFTIKPKYGFGTAGSEKYNIPPN 235
*:** *:: * **:**: .:*:*::***: *:: *:.:: : *:**** **. *:.* **

FKBP51
DrFKBP52

AELIYEVTLKSFEKAKESWEMDTKEKLEQAAIVKEKGTVYFKGGKYMQAVIQYGKIVSWL 298
ATLQYKIKMKAFEKAKESWEMNTIEKLEQSVIVKEKGTQYFKEGKYKQAIVQYKRIVSWL 295
* * *::.:*:**********:* *****:.******* *** *** **::** :*****

FKBP51
DrFKBP52

EMEYGLSEKESKASESFLLAAFLNLAMCYLKLREYTKAVECCDKALGLDSANEKGLYRRG 358
EHESSMQPDDEEKAKALRLAAYLNLAMCYLKLQDANPALENCDKALELDANNEKALFRRG 355
* * .:. .:.: :::: ***:**********:: . *:* ***** **: ***.*:***

FKBP51
DrFKBP52

EAQLLMNEFESAKGDFEKVLEVNPQNKAARLQISMCQKKAKEHNERDRRIYANMFKKFAE 418
EALVVMKEFDMAKVDFQRVIELYPANKAAKSQISICQKHMREQHEKDKRLYANMFQKFAE 415
** ::*:**: ** **::*:*: * ****: ***:***: :*::*:*:*:*****:****

FKBP51
DrFKBP52

QDAKEEANKAMGKKTSEGVTNEKGTDSQAMEEEKPEGHV 457
RDAKEADQEKEQDKKQNGSAME--IDENAAQEQTAA--- 449
:**** ::
.*..:* : *
*.:* :*:..

Figure 4.3: ClustalW2 Sequence Alignment of FKBP51 and DrFKBP52
Sequence was aligned using ClustalW2 alignment software. Accession numbers:
NP_001139247 (FKBP51) and NP_958877 (DrFKBP52).
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4.2.2 DrFKBP52 and DrFKBP52-A111V Modeling
I-TASSER predicted five 3D models for each structural query. The loop region
was stacked to determine whether the loop region maintains a similar conformation in
all predictive models. While slight variations are seen they are insignificant, indicating
that homology modeling for each model has a similar conformation. This gives us
confidence that the predictive modeling for both targets, DrFKBP52 and DrFKBP52A111V, were successful and precise. Because the A111V mutation is located at the
proline-rich loop region, only the loop was isolated for further analysis, Figures 4.4 and
4.5.
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Figure 4.4: Overlapping of Wt-DrFKBP52 Homology Models
Predictive models were overlapped using PyMOL, each model is highlighted in different
colors.
103

Figure 4.5: Overlapping of DrFKBP52-A111V Homology Models
Predictive models were overlapped using PyMOL, each model is highlighted in different
colors.
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4.2.3 Hydrophobicity Scale of Wt-DrFKBP52 and DrFKBP52-A111V
The hydrophobicity on the surface of the loop was assessed in wt-DFKBP52 and
DrFKBP52-A111V to allow us to further evaluate what changes may be relevant in their
functional divergence. We determined that there is no change in the overall shape or
geometry of the loop, figure 4.4 and 4.5. However, the valine substitution at position 111
does affect the surface charge (to more neutral) and the hydrophobicity (to more
hydrophobic) in the vicinity. This result is expected in all the predicted models, as the
position of the Ala 111 or Val 111 relatively stays the same. Hydrophobicity models
indicate an obvious change in surface area above the loop region between both FKBPs,
see figure 4.6 A, B. This change in surface charge could be very important in
understanding the necessary interaction between AR:hFKBP52.
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A.

B.

Figure 4.6: Hydrophobicity Scale of DrFKBP52 and DrFKBP52-A111V
The surface of the proline loop region was analyzed for hydrophobic intensity using
PyMOL. (A) Wt-FKBP52. (B) DrFKBP52-A111V.
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4.2.4 Comparison of FKBP Proline-Rich Loops
Homology modeling was utilized to further delineate the structural significance of
position A111 and A116 in DrFKBP52 and hFKBP52 respectively. The bioinformatics
software used compares one known protein structure to a highly similar unknown
protein to predict the unknown protein structure. Using this method we discovered a
very interesting conformational distinction between the DrFKBP52, hFKBP51 and
hFKBP52 proline-loop regions. Figure 4.7 illustrates the predicted surface of the prolinerich loop from the various FKBP proteins and suggests a closed conformation for both
hFKBP51 and DrFKBP52, while hFKBP52 has a more open conformation. The same is
seen in the stick model, hFKBP51 L119 and S124 are in close association above the
loop region and analogous residues in DrFKBP52 (P114 and P119) are also hovering
over the loop region (Figure 4.7B). However, the DrFKBP52-A111V mutant is predicted
to have a more open conformation similar to that of hFKBP52, both space-filled and
stick model shows an unobstructed pocket above the proline-loop (Figure 4.7A, B). This
is further corroborated by the hydrophobic surface modeling, which demonstrates how
the proline-rich loop on both hFKBP52 and DrFKBP52-A111V, but not DrFKBP52 and
hFKBP51, forms a hydrophobic pocket more conducible to protein-protein interaction
(Figure 4.7C).
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hFKBP51

hFKBP52

DrFKBP52

Dr52-A111V

A

P124

B

P119

A116

A111V

S124

P114

L119

P119

A111

P114

P119

A116

C

Figure 4.7: Homology Modeling of the FKBP51, hFKBP52, DrFKBP52 and
DrFKBP52-A111V Proline-Rich Loop Region
(A) Homology modeling was used for comparison of hFKBP52 and FKBP51 to
determine conformational changes induced by the DrFKBP52 A111V mutation. Crystal
structures of FKBP51 (lkt0A.pdb), FKBP52 (1q1cA.pdb), DrFKBP52, and DrFKBP52A111V are aligned; the respective FK1 domains were isolated and space-filled modeling
and (C) hydrophobic surface conservation was done (B). Note that the only differences
between FKBP51 and FKBP52 within the loop region are at positions 119 and 124.
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4.3 DISSCUSION
To gain some insight into the potential role that the valine plays at position 111
and 116, predictive homology modeling was performed on DrFKBP52 and DrFKBP52A111V. A close comparison of the corresponding loops in hFKBP52, FKBP51,
DrFKBP52-A111V and DrFKBP52 (Figure 4.7A ,B, and C) reveals a striking structural
difference due to the respective amino acids at position 111 and 116. The DrFKBP52
proline side chains (P114 and P119) protrude into a hydrophobic notch formed along
the top of the loop, more similar to hFKBP51. The projection of these two residues is
significantly altered by the addition of valine at position 111. The conformation of its
proline spread more outwards, similarly to hFKBP52. Hydrophobic surface depictions
show that hFKBP52, hFKBP51, DrFKBP52-A111V and DrFKBP52 all possess a
hydrophobic surface above the proline-rich loop. This surface is blocked by the
projection of surrounding residues in DrFKBP52 and FKBP51. Nevertheless, only
hFKBP52 and DrFKBP52-A111V retain an open conformation compatible for proteinprotein interaction. It is rational to conclude that DrFKBP52-A111V, in a manner
analogous to hFKBP52, forms a functionally important contact via the FK1 hydrophobic
notch with another component in the steroid hormone receptor complex. FKBP51 and
DrFKBP52 lack this contact due to the altered loop conformation imposed by the leucine
and proline, inhibiting adequate receptor interaction.
We propose that the FKBP52 FK1 domain, via the open conformation that
exposes the hydrophobic notch formed by addition of valine at position 116, forms a
specific contact with the receptor LBD and the highly positive region of the FK2 in the
context of Hsp90 heterocomplexes and that this contact potentiates receptor response
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to hormone. This theory is established in that we know that hFKBP52 binds Hsp90
directly and through this interaction potentiates the receptor. Additionally, studies have
shown that FKBP52-dependent potentiation is localized to the receptor LBD (25, 13).
Since hFKBP52 selectively potentiates the hormone-induced response of AR, GR, and
PR, but not the activity of the mineralocorticoid and estrogen receptors, we conclude
that the relevant FK1 interaction for potentiation is receptor specific, and not indirect
through Hsp90 (109, 113). We suggest that the hydrophobic notch that forms above the
proline-rich loop region could allow for a more efficient interaction, forming a LBD
anchor. Through this study we conclude that prolines in the loop region are not the sole
indicator of functionality, but structural integrity is key to maintain hFKBP52’s
potentiation of the steroid hormone receptor.
In summary we have shown that a single amino acid residue at position 111 and
116 near the PPIase loop plays a crucial role in the conformation integrity of the
hydrophobic notch created by the proline-rich loop region, in both DrFKBP52 and
hFKBP52. Since the PPIase loop is often involved in protein interactions, its
accessibility is an important determining factor in the function of steroid receptor
complexes. The identification of these critical residues is an important step toward
understanding the mechanism of hFKBP52 interaction with steroid hormone receptors.
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